With capital request accomodated, the company believes that Pain Away will jump in sales starting in 1996.
The company will attempt a public offering based on year 2000 earnings. If there is no public market and no prospect for a public market in the near future, then the company will offer to buy back the stock owned by the venture capitalist. A predetermined price could be set ahead of time, if desired by the venture capitalist.
The product effectiveness, evidenced largely through anecdotal evidence, personal testimonials, and repeat sales, has formed the basis for the future growth of the company. Together with a second, complementary product (nearly ready for market), the launch product will be aggressively mass marketed as a pain management system for the next five to ten years. Past and current sales have been to end-users, health professionals, and to some retail chains. The company and product are now poised for first stage expansion. Over 30 target wholesale markets have been identified. While the company uses its marketing strategy to enter these wholesale markets, simultaneous efforts will be made to develop research protocols. Management is confident that the anecdotal evidence and personal testimonials will be strengthened by controlled studies, designed to test the effectiveness of the product and demonstrate the physiological healing activity stimulated by the formula. With scientific credibility, the product will not only build its position in the $150 million homeopathic product category but will also strengthen its transition into the formidable mainstream topical analgesic category.
Future research is planned, based upon inquiry, in order to adapt the formula for animal use (Pain Away currently being tested on thoroughbred horses).
At the end of five years, the company intends to have at least one additional health product and should be able to go public off its revenues. The long-term goal for the company is to become an entrepreneurial leader in the development of natural products for various segments of the health care market. The company plans to capture enough share of the topical analgesic market to become either a viable joint venture partner or an acquisition candidate.
The product formula and delivery system are proprietary. The formula is uniquely advanced and is nearly immediately effective in relieving pain. Homeopathy and immunization have much in common, namely the principle of similars, which states that whatever a substance causes in a large dose, it can stimulate an immune response to defend against it in a small dose. It works by the principles of stimulation to the body's own self-healing mechanism and by the scientific balancing of its natural active ingredients through a dilution process called micro-dosing. Micro-dosing has given homeopathy its 200-year history of safety with no known side effects or toxicity. This self-healing process is in contrast to the majority of commercially successful topical analgesics, which contain counter-irritants, including the newer capsaicin-based products. These ingredients cause a superficial inflammation on the skin which masks pain by deadening the sensation of pain in the epidermal nerve endings only, or by distracting from the perception of pain by irritating an area near the pain source. The Pain Away formula has been developed with precision and balance and is a product that is effective and safe for use on all skin types. Pain Away's eleven active ingredients stimulate improved circulation in the micro-capillary system to ligaments and tendons, where most pain is felt. Pain relief is the result of the body's self-healing.
The manufacturing is sub-contracted out to a highly respected FDA-licensed manufacturer of homeopathic products.
An important unique feature of Pain Away which distinguishes it from other homeopathic remedies is that Pain Away is a topical treatment and is not a systemic treatment. As such, it requires little knowledge to use and is conducive to cross-merchandising in the mainstream analgesic category. Furthermore, since Pain Away is a formula of ingredients, it provides a broad spectrum of effects as compared to single remedies.
The personal commitment of the founder to relieve his own pain also adds a unique value to the story of this product - a story which can enhance marketability - to anyone who is in pain or anyone who knows someone in pain.
Although Pain Away is an homeopathic product, the company will position itself as a natural ingredients company - not necessarily homeopathic. All the company principals plan to engage both septics and advocates of complementary medicine by applying rigorous scientific standards equally across the board, for both conventional and unconventional treatments. Contacts have already been made with the National Institute of Health regarding future research.
The product is a specialty consumer good carrying a suggested retail price of $19.95 for a 3.7 oz. jar (1.9 oz. jar also available at $12.95). The jar is designed with a medical appearance. The jar is easy to ship in multiples, is easy to stack on a shelf, is aesthetically pleasing, and has an easy-to-handle screw cap. The actual cream is greaseless, easy and pleasant to apply, and is odorless. Pain Away has, to date, largely been sold directly to end-users, and wholesale to retailers, distributors, and catalogues. The markets have supported the suggested retail price, which was arrived at by surveying market research supporting the $19.95 price along with the perceived value of the product compared to similar products at about the same price. This price also yielded a gross profit of $3.75 per jar and allowed for 100% markup from wholesale.
The eleven ingredients are readily available through top-quality labs which control for purity and authenticity. The cream is compatible with any medication being taken. The product carries a money-back 30-day guarantee.
Preliminary studies done by independent treatment professionals (no control group used) have shown that Pain Away has been effective for relieving the pain, inflammation, and spasm associated with arthritis, bursitis, sciatic spasm, neck and back pain, tendonitis, tennis elbow, tension headache, achilles tendonitis, and carpal tunnel syndrome. Anyone suffering these ailments, treating these ailments, or caring about anyone suffering these ailments is a potential purchaser of the product. A New Jersey hockey team uses Pain Away prior to workouts, competition, and for pain relief. The head trainer for the team says, "There's no product better for contusion of the quadriceps." He has reported shorter recovery times as a result of using Pain Away. Reports from athletes are that using Pain Away before and after workouts yields less cramping, fatigue, and soreness.
Top purchasers of TPR to date:
Mall Booth Marketing | $11,000/month | 800/month |
Direct Selling-Retail | $16,000/month | 1200/month |
The total market for OTC internal and topical analgesics is estimated at $3.6 billion for 1995 and is projected to be $4 billion by 1997. With over 400 brands saturating this mature market, growth is still occurring through new products and product innovations. Driving this growth are:
The market is dominated by internal analgesics:
Internal OTC analgesics: | 3,001.6 | 3151.7 | 3,282.5 | 3,340.2 |
Aspirin | 840.4 | 819.4 | 787.8 | 756.8 |
Acetaminophen | 1260.7 | 1339.5 | 1411.5 | 1496.5 |
Ibuprofen | 900.5 | 992.8 | 1,083.2 | 1/086.9 |
Topical OTC analgesics | 315.4 | 402.1 | 522.7 | 692.6 |
Pain Away is a new product to this sizable OTC pain-relief market. It will enter this large arena riding on its effectiveness and coming from the new and growing alternative health care market segment. As a new OTC product, Pain Away has such a broad-based appeal that it will be sold to a large portion of the total OTC pain-relief market (both internal & topical), estimated to be 84% of all US adults and growing as the baby boom population ages and concerns regarding age-related ailments, such as arthritis, increase. Of this 84%, about 25% alone use pain-relief products for body/muscle pain for which Pain Away is especially suited. Just this one type of ailment offers a substantial market potential:
161.3 Million X | 40.3 Million X | 156x/year | = | 6.3 Billion uses |
If only 40.3 million Americans (25% of 84% of adults) use an OTC pain-relief product three times a week for body/muscle pain alone, then the market potential is 6.3 billion uses of a pain-relieving product per year. Past use of Pain Away has indicated that a minimum of 3 applications per week would use about one 3.7 oz. jar per month. A conservative yearly estimate would be 10 jars per year, with consistent use. In order to reach a five-year sales goal of $50 million (6.7 MM jars), 667 MM consistent purchasers (10 jars/yr.) are needed. Product history has indicated a consistent 80% reorder rate, so at this rate, 833,000 original purchasers are required. This figure is 2.07% of just this one market segment. The company is very confident that it can capture 2.07% of this market segment within five years, especially considering that the roughly 40 million Americans who exercise on a regular basis, and who are aging, are included in this segment. Anecdotal reports from athletes who use Pain Away are that it can prevent injuries by "warming up" vulnerable muscles and joints prior to a workout. The product has wide applicability within this segment. The table below shows the percentage of the body/muscle pain market segment required to meet the next 5 years of sales projections.
(in millions) | (with 80% reorder rate) | ||
1996 | $3 | 50,000 | .12% |
1997 | $8 | 133,000 | .33% |
1998 | $18 | 300,000 | .74% |
1999 | $32 | 533,000 | 1.32% |
2000 | $50 | 833,000 | 2.07% |
These numbers are based upon a wholesale price of $7.50 per jar and a usage rate of 10 jars/year with a segment population of 40.3 million potential purchasers.
The prescription pain relief market is a distinct market which Pain Away will not attempt to penetrate. Pain Away can, however, compete directly with nearly all pain-relief products because of its unique identity of being both a substitute and a supplement to ail competing products. This uniqueness fits a projected market shift from internal to topical analgesic use as the population ages, and derives from 2 factors: 1) Use of Pain Away can reduce the needed dosage of any pain-relieving medication and 2) Pain Away is already part of a rapidly growing segment (25%-30%/year) of consumers who use alternative health care because of a disenchantment with OTC drugs and a concern about side effects with adverse reactions. Use of Pain Away can reduce needed dosage of other pain-relieving medications. As stated earlier, Pain Away's effectiveness is based upon the homeopathic principle of microdosing. While it promotes self-healing by stimulating blood flow to micro-capillaries, it remains safe for all skin types and with use of any other medication. Anecdotal evidence (from hospitals, some doctors, and occupational rehab center) has indicated that use of Pain Away alone has yielded positive results and use of Pain Away, along with other treatments, has seemed to accelerate recovery. As always, this kind of evidence will be scientifically studied. The salient point is that Pain Away can be a substitute and/or a supplement in pain management, and thereby reduce needed dosages of other medications.
Homeopathy, being an established (officially recognized by UK National Health Service) and significant alternative mode of treatment, is gaining increasing acceptance in mainstream American health care. The National Institute of Health has even awarded grant money for research in alternative treatments, including homeopathy. Drug retailers report that homeopathy may be the fastest-growing category in the trade class of drug chains. Since homeopathy is gaining acceptance as an alternative treatment, the market segments which are already embracing these alternatives will continue to be targeted in the company's initial expansion. These segments include people ages 25-elderly, who seek improved quality in life, and whose lifestyle values involve "newness." This segment includes most of the "baby-boomer" population, estimated at over 75 million. The market of alternative health care seekers is characterized by patients who can and will pay for their own care. As much as 70% of alternative medical treatments are still paid for by patients themselves rather than insurers. This kind of purchasing indicates a willingness to try an alternative product and continue purchasing based upon perceived value of the product's effectiveness. Company management has been encouraged by the consistent 80% reorder rate and knows sales will be sustained once initial purchases are made. The alternative health care market is of respectable proportion. According to the New England Journal of Medicine (1/28/93), 34% of Americans spend $13 billion/year on alternative treatments such as chiropractic, acupuncture, massage, and homeopathy. Pain Away is already marketed to all of these treatment specialties so it will reach the spectrum of alternative treatment. This 34% of Americans are familiar with the term "homeopathic," so there's a consumer predisposition to being further educated about homeopathy as a value-added natural ingredient alternative.
The company will build an early market position on the alternative health-care market and will join the growth of the homeopathic segment as it moves from the fringes to the mainstream of the OTC pharmaceutical market.
Alternative Market Potential:
262 Million × | 89.1 M (34%) × | 24x/Yr. | = | 2,000 Billion |
If only about one third of Americans use an an alternative pain-reliever just twice per month, then the market potential is 2 trillion uses of an alternative pain-relieving product per year. Market indicators are that both the number of users and the frequency of use will increase as the population ages. The use rate of 2 times per month converts to 2 jars of Pain Away per year with consistent use. Again, in order to reach the 6.7 million jar sales goal ($50 MM), at the re-order rate of 80%, Pain Away would have to make 4.2 million initial sales in order to sustain 3.3 million consistent purchasers. This size customer base comprises 4.71% of the growing alternative health care market. The company believes that this sales goal is attainable within the next five years. The table below shows the percentage of the alternative health care market segment required to meet projected sales.
(in millions) | (with 80% reorder rate) | ||
1996 | $3 | 250,000 | .28% |
1997 | $8 | 667,000 | .75% |
1998 | $18 | 1,500,000 | 1.68% |
1999 | $32 | 2,700,000 | 3.03% |
2000 | $50 | 4,200,000 | 4.71% |
These numbers are based upon a wholesale price of $7.50 per jar and a usage rate of 2 jars/year with a segment population of 89.1 million potential purchasers.
The market potential for pain relief products is huge. By narrowing the focus to product category sales, the potential becomes more exact. Pain Away's product category is within the topical analgesic market, estimated at $402.1 MM annually with a projected $522.7 MM market in 1996 (30% growth) and $692.6 in 1997 (32.5% growth). Starting with $522.7 as the base market volume, and with 30% growth per year for the next 5 years, Pain Away would have to capture 3.33% of the year 2000 market volume to make its sales goal of $50MM. Management believes that these goals are attainable.
The table below shows what percentage of the topical analgesic market will meet Pain Away's sales projections.
$522.7 | $692.6 | $900.3 | $1,170 | $1,521 | |
$3 | .57% | ||||
$8 | 1.16% | ||||
$18 | 2.00% | ||||
$32 | 2.73% | ||||
$50 | 3.29% |
The focus can be narrowed further to the homeopathic product category, which is growing at a rapid rate at this time. The dollar volume of this segment is estimated at present to be between $150 million and $215 million and expected to grow at a rate of 25% to 30% a year. Some market-trackers say that retail sales haven't grown enough to support the existing number of homeopathic manufacturers and that a shakeout will consolidate sales in the hands of fewer manufacturers. The forseeable trend, however, is progressive growth from the fringes to mainstream markets, and at a rapid rate. The table below again shows percentages of this dollar volume required to meet sales projections.
$182.5 | $228.1 | 285.2 | 356.5 | 445.6 | |
$3 | 1.64% | ||||
$8 | 3.51% | ||||
$18 | 6.31% | ||||
$32 | 8.98% | ||||
$50 | 11.22% |
These numbers are based upon a 1996 volume mid-point between the projected volume range of $150 MM and $215 MM. Growth rate is 25% a year. At first glance these percentages may seem daunting. However, the manufacturers supplying this niche are relatively few in number and therefore hold significant market shares A new player can get a reasonable market share with the right product and marketing plan. The mainstream merchandising of homeopathic products started in the early '90's and has been tested as a lucrative direction. Company management is very confident that Pain Away will gain enough share points to capitalize on the rapid growth of this product category. Pain Away will not remain in the homeopathic niche. Its effectiveness will make it competitive with mainstream topical angalgesics.
The company will also develop an international market. A 10,000-unit order has already been received from a distribution company in Hungary and is awaiting final approval from the Hungarian State Department of Pharmacy. A small order was also sent to well-known sports figure in Spain. Discussions are underway for this individual to start large-scale distribution. The homeopathy market in the UK is estimated at 18M pounds and in Germany at 120M pounds, so European marketing could be strengthened by the homeopathic identity alone. In Germany, an independent division of the German Federal Health Agency publishes monographs on the safety and efficacy of herbal medicines. The company believes that Pain Away would fare excellently under such review and will carefully research and plan when and how to reach such markets.
There are many companies competing for shares of the 3.6 billion dollar OTC analgesic market. The major players are the internal analgesic manufacturers:
Reynolds | Aspernol | 1.2B | 34% |
Pharmacorp | Aspiril | 612 MM | 17% |
American Pharmacy | Anaprin | 180 MM | 5% |
Oxford Co. | Maraprin | 180 MM | 5% |
Jones-Smythe Benton | Aspirin | 144 MM | 4% |
The balance of the OTC internal analgesic market is held by private label companies and "others." The major strengths of this level of competition are obvious in comparison to Pain Away's present market position. The major players have:
An important competitive strength of Pain Away is that it is topical - pain relief is accomplished without risk of overdose and consequent risk of serious side effects. This competitive strength derives from a previously noted shift in the market from internal to topical analgesic use. This shift in consumer preference, along with Pain Away's effectiveness, can position the product as a substitute/supplement among these large competitors. Management is ever mindful that mainstream pharmaceutical companies are watchful of the homeopathic market and will act accordingly should market share be lost to homeopathic remedies. Becoming a viable acquisition candidate to any one of its major competitors is a realistic goal. Pain Away management is committed to quality product development and is also open to strategic alliances which would enhance its market capability.
The competition in the topical analgesic market is head-to-head. The top competitors are:
Pepper Co. | Pepperub | Menthol | 60.3 MM | 15% |
Athens | Vapol | Menthol | 47.9 MM | 11.9% |
Lucia | Menthol Plus | Menthol | 35.8MM | 8.9% |
Skin Care Corp. | Zanprin | Capsaicin | 44.2 MM | 8.7% |
Bioderm | Aspratin | Salycin | 18.8 MM | 5% |
Capcreme | Capsaicin | NA | ||
Men-Thol Co. | Menthoflex | Menthol | NA | |
Capthol | Capsaicin | Menthol | NA | |
Bianco-Picard | Salicreme | Methylsalicilate | 86 MM | |
Synergy | Lyptum | Eucalyptus | NA |
The basis for the competitive analysis is Pain Away's most competitive feature:
All topical analgesics contain counter-irritants, including camphor, menthol, methyl salicylate, eucalyptus, wintergreen, and even the popular capsaicin. These ingredients, even when blended, act primarily to cause a superficial inflammation on the skin. This inflammation serves to hide the pain by deadening pain receptors in the skin.
What distinguishes Pain Away from all of the above products is that the eleven active homeopathic ingredients stimulate the blood flow in the body's micro-capillaries and act synergistically with the body tissue. This stimulates the body's own self-healing. Pain is treated at its source. Company management believes that the unique effectiveness of Pain Away will give it competitive clout. The issue then becomes how to compete.
Although Pepperub (Pepper) and Vapol (Athens) enjoy the largest market share, they are vulnerable to new product introductions. Menthol Plus (Lucia) held the top position in this category last year until Pepperub was re-packaged and relaunched with line extensions. That relaunch along with a relaunch of Zanprin boosted sales of both brands and put Pepperub back on top. Pepperub, Vapol, and Mentholplus are all menthol-based products. Zanprin is a capsaicin-based product and has boosted usage of its relatively new ingredient. Other relatively new capsaicin products are Capcreme (Bioderm) and Capthol (Men-Thol Co.).
Company management believes that Pain Away is generally more effective than Pepperub and Vapol. However, these venerated brand names, large advertising budgets, and consumer loyalty are formidable competitive advantages. Pain Away will focus on other competitors in order to gain a market position.
The key competitors are Menthol Plus, made by Lucia and Zanprin, made by Skin Care Corp.. Menthol Plus is a menthol-based product which Pain Away has encountered head to head in the sports market. Menthol Plus has a retail price advantage in the mass market, selling for $4 for a 2 oz. tube. This price difference is of little concern because Pain Away will promote itself as a high value product. The topical analgesic, alternative health, and homeopathic markets all support pricing based on perceived product value. Menthol Plus' manufacturer has reduced the advertising budget for this product (about $2 million) recognizing from a 21% decrease in 1994 sales that the product has matured. The company plans to acquire other brands (no topical analgesics) and extend its other lines in order to generate sales growth. The company sells another topical analgesic which is doing well in sales but has not reached the same position as Menthol Plus. Pain Away will monitor the life cycle of Menthol Plus and move to gain any market share it might lose.
Zanprin, made by Skin Care Corp., is gaining market share because Zanprin (.025%) and Zanprin- X (.075%) are capsaicin-based products. Capsaicin, derived from cayenne peppers, has created a new segment in the market and is very popular. Other companies are making capsaic in products but Skin Care Corp. attracted market attention by relaunching Zanprin as an OTC consumer product. It had been marketed for seven years to physicians and kept behind the counter, carrying the credibility of a prescription product. In early 1995, the product was re-packaged for shelf space and supported by TV ads. Despite commanding premium prices ($19.95/2oz of Zanprin-X), the product has done dramatically well.
Skin Care Corp. claims that Zanprin is the "only brand with physician endorsement and specific clinical support." This is a credible claim, cultivated for seven years, and obviously contributing to sales of the product.
Skin Care claims to be the first in the industry to develop their highly purified version of capsaicin for a pharmaceutical base. Zanprin distinguishes itself by promoting controlled clinical studies which have supported its effectiveness. Skin Care claims that such clinical trials don't apply to other, less pure, capsaicin formulas. This scientific feature enhances product credibility among physicians and pharmacists.
The management of Pain Away Ltd. recognizes the effective marketing strategy used by Skin Care because it is similar to their own strategy. Advertising and promotion expense is critical. With proper capitalization, Pain Away can compete because the Pain Away homeopathic formula is unique and effective. Many capsaicin users, including Zanprin users, have complained about the burning sensation caused by capsaicin. Pain Away will stand up to any topical analgesic on the market and do very well with comfort, safety, and effectiveness. The company needs to get this message out. The seven-year product life of Zanprin, supported by unique and heavy TV advertising, gives Zanprin quite an edge. Zanprin is now a "new" growth product and Pain Away can grow behind it, by comparing ingredients and effectiveness at every turn. Pain Away is also in the same price range as Zanprin, doing slightly better with $19.95 for a 3.7 oz. jar or $12.95 for a 1.9 oz. jar.
Zanprin is not the "only brand with physician endorsement and specific clinical support." Pain Away has been cultivating health professional support since the R&D phase. The product is heavily endorsed, and more medical support is developing. Many of Pain Away's sales to date have been to health professionals. Regarding clinical support, Skin Care's success with this strategy underscores the strategic importance of Pain Away's plans for controlled clinical studies.
Speaking of "highly purified" formulas, Pain Away can compete strongly with any formula on the market, especially capsaicin-based. The company wants to discuss purity of ingredients and formula and will do so in all promotional efforts.
The remainder of the products listed in the top competitor list have of course the same advantages that any established company with significant market share has. Beyond these immediate competitive advantages, Pain Away can compete, again, on the ingredient effectiveness basis.
Aspratin, an odorless rub which contains Salycin, sold well when it was introduced in 1992. It held third place among topical analgesics at the end of 1993. It has since been surpassed by capsaicin-based Zanprin. Bioderm developed Capcreme and lowered its price when Zanprin was relaunched.
Capthol was recently developed by the long-established Men-Thol Co. and is a capsaicin-menthol blend designed to compensate for the sometimes delayed pain relief when using capsaicin alone.
Salicreme is a methylsalicylate product which has shown flat growth and has lost market share.
Lyptum was a rapid-growth product in 1990-1991 but has since lost market share. Besides the well-established brands like Pepperub, the products which are gaining in this market are the capsaicin-based. This product category is known to be affected by product innovation and development. With proper support, Pain Away will take a respectable market share.
The competition takes place in the drug chain arena. Homeopathy may well be the fastest-growing category in the trade class of drug chains (20% of all homeopathic product sales). Among the growing number of drug chains which are giving shelf space to homeopathic products are: Walgreens, Medicine Shoppes International, Thrifty Payless, Eckerd Corp., Edgehill Drugs, Genovese and FEDCO, a California supermarket chain. Research published in the Journal of Clinical Pharmacy and Therapeutics states that 27% of US pharmacists consider homeopathic medicines helpful while only 18% consider them useless. The crossover of homeopathy from health food stores, where sales are still strong, to mass markets is gaining momentum.
As mentioned earlier, there are relatively few companies supplying homeopathic products to the mass market. There are five major producers/distributors of homeopathic products.
Health System Products | Full line of products |
Homeopathic Co. | Full line under brand name Organa |
Life-Right Corp. | Full line |
Del Sol Inc. | Full line |
Scandinavian Co. | Full line |
Bio Health | Full line |
Health System, Homeopathic Co., and Life-Right pioneered the distribution of homeopathic products to chain drug stores in the early 1990's and are now market leaders, although more companies are entering this lucrative market. Health System Products now has about 40% market share. Homeopathic Co. and Del Sol are aggressively developing the crossover into mass marketing with line development and heavy TV advertising.
All the topical analgesics listed above are arnica-based, with few other ingredients. Arnica Montana is the premier homeopathic medicine for the treatment of shock and trauma to the muscle. These formulas come the closest to Pain Away's because they contain some of the essential homeopathic pain-reducing ingredients. Pain Away's formula, however, blends more ingredients than any other homeopathic topical analgesic on the market. This more inclusive formula gives the product wider applicability. Price-wise, Pain Away is more expensive than most of the competing homeopathic products, where prices are in the $5-$10 range for 2oz.-4oz. sizes. But, this is a value-priced market, so price is not a critical variable. Since Pain Away is very competitive on an ingredient/effectiveness basis, the critical factor is having the resources to promote the product.
As has been noted, the topical analgesic category, including natural ingredient, is rapidly influenced by new clinical studies and product innovations. There are three main sources of new competition:
Pain Away Ltd. can be very competitive with the right promotional support.
Increase market share by reducing market share of competitors. This strategy will capitalize on the market development to date and capture a share of markets held by existing pain-relieving topical applications. The key benefit is that conventional pain-relievers mask pain while Pain Away stimulates the body's own healing ability to directly battle an ailment. Another benefit is that homeopathic remedies have no known side effects while many pain-relievers, especially those ingested, have side effects. Neither will Pain Away interfere with any medication. This strategy requires extensive advertising in mainstream media, including infomercial, QVC (Pain Away already under review), 60 second commercial, cable TV, interactive TV, direct mail, independent sales reps, POP displays, and educational inserts/newsletters. One objective of planned controlled studies on the effectiveness of Pain Away is to use scientific evidence to help bridge the narrowing gap between natural and conventional medicine. Product studies will support this marketing strategy. In this context, the company will pursue preliminary inquiries from a favored vendor to use Pain Away in the workplace to study any reduction of lost work time and/or medical costs precipitated by repetitive stress injuries.
Expand a growing new market for alternative health care by positioning to lead this growing market. This strategy involves specialty catalogues (placed in 5 currently), placement on retail shelves of health food stores, educational product inserts/newsletters, media appearances discussing product, and independent sales reps. This strategy addresses the 89.1 million users of alternative health care.
The company has already been approached by two large Multi-Level Marketing companies. This strategy would involve creating private labels for a large customer. Of utmost consideration with this strategy is product identity and how this channel of distribution would affect it. This channel of distribution usually requires more price mark-up than the product would tolerate.
The company will create its own "competition" by developing private labels and/or separate companies to market to different niches.
Keep capital outlay to a minimum by licensing/franchising Pain Away to a brand-name company. This strategy would add value to the product in the form of brand name loyalty, manufacturing strength, and a strong sales/service force already in place. The company envisions its role in this type of strategic alliance as conducting scientific studies to increase the credibility of TPR and in developing new products. This strategy remains an option which could preclude other strategies under mutually acceptable terms.
Building on an initial order from a health product distribution company in Hungary, Pain Away Ltd. will penetrate the European market by targeting England and Germany, where homeopathy is an accepted form of treatment. This strategy would be developed only after a US market position was established.
The company is moving from start-up stage into its first growth stage. Market strategy to date can be succinctly described as selling "one jar at a time." Direct personal selling has been the mainstay in sales growth. This strategy has targeted any end-user willing to try the product. These early customers were reached through health care professionals and direct selling through state/county fairs, shopping mall space, health food store chains, and most recently lifestyle catalogues. As the company moves away from direct selling, a strategy which proved to be an excellent market test, into mass-marketing, identified market segments are being matched with appropriate distribution channels. The plan now is to expand and concentrate more on helping the consumer develop product preference by heavy advertising of the brand name, the benefits of the product, the ease of use, and the guarantee. Company expectations are that all advertising will be enhanced by results of controlled studies of product effectiveness.
The company intends to expand regionally, based on existing markets and consumer profiles (e.g., households from the South are likely heavy users of analgesics). The national market will only be tested by placement in catalogues with a distribution of 200 million. As regional sales grow and as the product gains recognition, then a national marketing strategy will take shape. Company management have begun discussions with a major marketing communications agency (Fortune 500 client list) who themselves approached Pain Away. The marketing and sales outline is as follows.
Utilize a sales organization enabling direct-call coverage on the top 25 customers, which generally account for 80% of retail sales, and broker-managed coverage for the remainder. Launch plan would include a national sales meeting and all necessary materials.
Concentrate on the pharmacist community via co-op direct mail. Pharmacist recommendation at the purchase counter does affect sales.
The production process takes place in a standard homeopathic laboratory where raw materials are blended. There are no significant health or safety risks involved. Production orders are processed by purchase order for finished product. Some raw materials are usually on hand but more are ordered against purchase order requirements. Jars are ordered from a separate manufacturer and sent to the homeopathic laboratory to be filled, packaged, and shipped to Pain Away Ltd., where fulfillment is done.
The homeopathic laboratory has the capacity to fill all projected orders. As orders increase, Pain Away management will consider using a fulfillment service and more drop-shipping to wholesale customers. Cost of goods is estimated at 18% of gross sales. This figure has been consistent throughout production to date and is based on the complete production cycle.
There is no backlog.
The production process does not require any specialized or proprietary machinery. The critical factors in the production process are the highest quality of raw materials and the incubation process, which assures a stable finished product. Water is added to a base of vegetable/plant emollients. The eleven active ingredients are then mixed into the emulsion, which incubates for about 48 hours in large vats, while monitored for any fungal invasion. The finished product is then lab-tested for potency, which is done by lot number (the company gets lot samples). Filling is currently done by gravity-feed. The manufacturer might advance to computerized filling. One batch is 500 gallons. Lead time from order to packaged product is 4 weeks. Only a skilled and experienced manufacturer can produce the formula. Even other homeopathic manufacturers not familiar with a cream-based product would have difficulty with the production process. General topical analgesic manufacturers would need to become familiar with the raw materials and the production process in order to blend Pain Away's eleven active and ten inert ingredients. The company currently has one back-up manufacturer, which has never been used.
The company administrative staff consists of 5 people (recently reduced by 3) including the 3 officers. The two employees are paid an hourly wage. The staff are not unionized and there is no expectation of such. The labor supply in the region is more than sufficient to meet all future staffing needs. The sales force is comprised of independent agents who are paid on commission.
Herbal Laboratories | 35,000 jars | all raw materials |
Portland, Oregon | jars & caps | |
labels | ||
packaging | ||
shipping boxes |
Currently, the laboratory procures all production materials. There are no shortages of key components, and multiple sources are available.
All production is sub contracted out. Only fulfillment and shipping are done in-house. The company has formed a strong working relationship with Herbal Laboratories, which is the key subcontractor. Although management has selected a back-up manufacturer, the existing relationship with Herbal Labs has been more than satisfactory, so no change is foreseen. Other subcontractors supplying jars, labels, and boxes are used based upon price and service and can be replaced.
Standard office equipment is used for administrative functions. All production equipment at Herbal Laboratories is new and there is nothing that would cause production to be stopped for any appreciable time.
The company facility is a single-story 1,950 square foot, cement block structure on about a two-acre cleared lot that is leased in one-year increments. The facility is located in northern Dutchess County, NY. All necessary commercial and industrial infrastructure is in place. The facility is easily accessible from major thoroughfares. The general area has been and is recovering from the closing of 2 large industrial facilities, so there's been anoticeable decline in property values. There is, however, a regional effort to re-direct the area to rely more upon small and entrepreneurial business. Management plans to purchase the building in order to add an appreciable fixed asset and to reduce expenses. The structure is easily expandable, so the company will not have to move during its critical growth stage.
Active homeopathics are not patentable. Management is exploring establishing a trademark and a formula patent.
The three principals have invested collectively $100,000, which has been capitalized. Plans for the immediate future include forming a research alliance with a university, hospital, or research group in order to develop a protocol for applying the "rigorous scientific standards" against which the effectiveness of Pain Away can be proven. Management has projected R&D expenses at $ 30,000 for the next 12-month period. These expenditures are intended for controlled studies proving effectiveness, and for continuation of developing applications for animals. Management is sales-marketing oriented and does not want to develop only a research lab. Any R&D will be designed to enhance sales and profits. Company management is currently investigating an SBIR grant.
There are no particular federal, state or local laws/regulations that affect the conduct of business. The manufacturer meets OSHA requirements, as does the Pain Away administrative facility. The FDA regulates homeopathy as an OTC non-prescription medicine. Pain Away's ingredients are in total compliance with FDA standards. Mr. Peale cultivated a working relationship with FDA representatives during the initial research and wisely intends to sustain such.
Product liability insurance is underwritten. A buy-sell agreement among officers exists but is not yet backed by insurance. Key employee insurance is also yet to be written.
All taxes are current. The company pays standard payroll, Social Security, and corporate taxes. The product is sales tax exempt in many states.
Company principals first formed an S-corporation under the name Peale Inc. The realization of the likelihood of international sales prompted management to form Pain Away Ltd. as the operational company. Peale Inc. serves a limited partnership which was formed to attract investors. Both companies are run by the same management team. All R&D is done through Peale Inc. There is comingling of funds. This proposal seeks financing for Pain Away Ltd. Return on the investment will derive from the sale of the product Pain Away itself and any other products which the company sells.
Pain Away Ltd. is a member of the Homeopathic Manufacturers Association. The officers were invited to participate in an annual meeting of the newly formed FDA committee on natural medicines. This committee works on the bases for regulations, compliance, and claims for the natural ingredient industry, covering vitamins, herbs, and homeopathy.
Management subscribes to the following publications:
A board of directors will be developed in the near future. There is interest from the medical, nutritional, and professional sports communities, as well as from a local bank. Officers are:
Robert Peale - CEO Alana Curtis - President Ryan Lemon - Vice-President, Marketing
Profit and loss responsibilities are shared by the officers.
The officers are primary key employees (backgrounds in executive summary). Other key employees include:
Leslie Ottaviani - bookkeeper and office manager - known by management for 5 years and described as "a dedicated innovator with a true grasp for details." She has experience supervising 20 employees in the accounting department of Worldwide Airlines and has worked as an independent bookkeeper for several companies in Hudson Valley, NY.
Julia Allen - administrative assistant - known by management for 6 years and described as "having people and problem-solving skills and works incredibly well under pressure." Her background includes sales in a successful business which included business consulting.
Robert Peale | CEO | $1,600/mo. |
Alana Curtis | President | $1,600/mo. |
Ryan Lemon | Vice-President | $1,600/mo. |
Leslie Ottaviani | Bookkeeper | $12/hr.-35hrs/wk. |
Julia Allen | Admin. Ass't | $8/hr.-20hrs/wk. |
Davis Associates | Marketing Consultant | $5,000/mo.eff. 1/96 |
Public Communications Inc. | Public Rel. Consultant | $2,500/mo.eff. 1/96 |
Dr. Jeff Beck | Radio host sponsor | $2,000/mo. |
Cecil O'Connor | Finance Consultant | $80/hr. prepare bus. plan |
3% fee for securing funds | ||
Limited Partners (20) | Early investors | $.01/jarper $1,000 invested |
Jonathan Wainwright | Accountant | no retained\fee for service only |
Arnold Lee | Banker | no remuneration |
All other fees paid on an ad hoc basis. Different attorneys have been used on an ad hoc basis (finance closing fees will be paid by the company).
Robert Peale | 67 (1/3 of 200) | 33 1/3% | 23 1/3% |
Alana Curtis | 67 (1/3 of 200) | 33 1/3% | 23 1/3% |
Ryan Lemon | 67 (1/3 of 200) | 33 1/3% | 23 1/3% |
Investor | 0 | 0% | 30% |
Management is willing to negotiate any structure which suits the investor. The company is seeking an equity investor. Management will provide a seat on the company's board of directors. Ongoing reports of key ratios, profit-loss statements, balance sheets, and annual audits would be provided to the investor. It is management's intent that the investor will enjoy returns on investment in excess of that of alternative investments, as a privately held company, while providing investor liquidity of his investment by taking the company public at its earliest opportunity.
The existing capital structure includes a $50,000 unsecured line of credit with Poughkeepsie National Savings Bank. This line of credit was just brought to maturity in 1/96 for a 30-day period, at which time the line was renewed. If the current financing proposal is accomodated, then the line of credit can be increased.
Additional financing to date has derived from the sale of limited partnerships offering $.01 per 3.7 oz. jar royalty for every $1,000 invested. Each limited partner has been given the right to convert his/her capital investment into common stock when the company goes public, or, to receive back his/her original capital investment when the company goes public. Total amount of financing raised through the limited partnership is $100,000.
As mentioned earlier, officers have collectively invested about $100,000 in the company, mostly through the R&D phase. Officers' "sweat equity" is immeasurable.
As stated in the executive summary: Advertising & promotion campaign - $1,200,000 (see below); Market research - $300,000. The company anticipates the need for follow-on financing after 24 months of business.
Magazines | $330,000 |
Radio | $200,000 |
Shows & Conventions | $140,000 |
TV | $400,000 |
Retail Shops | $70,000 |
Sample-POP Display | $60,000 |
Management intends to preserve cash flow by factoring much of the receivables. With the current lead time of 4 weeks, however, some capital may be used to increase merchandising inventory in order to fulfill initial large orders. It is hoped that any follow-on financing can and will be debt financing, serviced by cash flow.
The following table sets forth the capitalization of Pain Away Ltd. as of 12/31/95 and as adjusted to reflect the proposed sale of common stock.
Common Stock, no par value, | (167,268) | 1,332,732 |
200 shares authorized; | ||
0 outstanding | ||
Additional Paid-in Capital | 1,500,000 | |
Accumulated Earnings (deficit) | (167,268) | (167,268) |
Total Stockholders' Equity | (334,536) | 1,165,464 |
Dilution: The net tangible book value of the company as of 12/31/95 was minus $1,673 per share. Without taking into account any other changes in such net tangible book value after 12/31/96, other than to give effect to the sale of 60 shares (proposed 30% equity share) hereby, the pro forma net tangible book value of the company on 12/31/95 will be $5,827 per share, representing an immediate dilution of $13,597 per share to new investors.
Price per share to Investor | 19,424 |
Net tangible book value before the sale | (1,673) |
Increase attributable to new investor | 7,500 |
Pro forma net tangible book value after the purchase | 5,827 |
Management recognizes that this proposed financing implies a large premium value on the existing equity and so will negotiate any other conditions which would induce the investor to make the investment.
At the time of the company's IPO, limited partners who opt for common stock will receive their shares from the officers' share of owned stock. The negotiated ownership held by the investor will not be further diluted.
Management seeks a close working relationship with the investor. The investor will be given one seat on the board of directors. Management would solicit consultations (for a fee) on financial matters, or any other area of investor expertise (e.g., planning, management development), but voting power is not an option. Fees will also be paid for any future financing and/or profitable business connections arranged by the investor.
Even though management feels that the company is at first-stage expansion, it is definitely still an early-stage company. Two obvious risks inherent in early-stage companies are undercapitalization and poor liquidity. Management has capitalized the business operations to date well enough to have developed the product and identified penetrable market segments. The current proposed financing will provide enough capital to handle the anticipated growth.
Management believes that it has the resources to continue at the present pace of business. An anticipated increase in sales through advertising media such as QVC , regional/national catalogues, retail outlets, and some European distribution can be financed by factoring. These "bootstrapping" approaches have sustained the company to date and will accommodate slow growth. Management believes, however, that more rapid expansion is desirable in order to penetrate its identified market segments. More rapid expansion requires more resources.
All officers have successful backgrounds in marketing. Additional experience in manufacturing/distribution has been gained in the past nine years of product development. Management has consistently shown a willingness to leverage themselves with accomplished professional consulting relationships. The company culture is one which reinforces sharing of expertise with mutual benefit to all concerned.
Any consumer product business is subject to the changing preferences of the marketplace. As presented in the marketing section of this proposal, the target markets are showing substantial growth, which limits uncertainty. There is currently a growing consumer preference for homeopathic topical remedies. More uncertainty is evident when considering competition, but can be made tolerable by on-going research and analysis.
The only uncertainty at present is whether or not the lead time (4 weeks) from purchase order to finished product can consistently be reduced. This uncertainty is of material concern as sales increase. Herbal Laboratories is a sound company with a promising long-term future and has always been customer-friendly, so no more serious uncertainties exist at present. Management believes that vertical integration of manufacturing is feasible in the long-term but is not practical in the near-term.
In the event that liquidation becomes necessary, management believes that the most value could be realized from the sale of the product formula itself. The formula is not patented, so valuation remains uncertain. However, the sales history, along with the testimonials attesting to the effectiveness of this "ready-made" product, should determine value. Office equipment would yield limited value, and unless the company building was purchased prior to liquidation, no value would be realized. Management believes that the company can and will generate increasing value in the near future, evidenced by increasing sales.
At present, CEO Robert Peale is considered the primary key manager/officer. His knowledge of the product ingredients, his history of public appearances promoting the product, his increasing recognition by the health community as an expert in natural medicine, and his charisma as a business professional highlight his key role. Managerially, the other officers are thoroughly competent and could manage the company and market its products without Mr. Peale. At this critical early stage, however, the product needs an identity and a market position before the loss of any key managers could be overcome. Once the premier product is securely launched and the product line is expanded, the loss of any officer could be absorbed by continued proper management of the company. Management believes that such a development is not far off, once the company is properly capitalized. Until such time, key person life insurance will be purchased.
Upgraded advertising campaigns could not lead to any substantial increase in sales. This problem can be avoided by using experienced advertising/marketing consultants who have familiarity with the targeted markets. Furthermore, properly designed test runs on any advertising campaign would provide objective indicators of expected returns. Capital investment in advertising should be gradual and progressively based upon certain expected levels of return.
Stronger competition could capitalize on and stall Pain Away's early success by replicating the product and its marketing strategy. This problem can be solved in two ways: First, with proper capitalization, Pain Away can make an entry into targeted markets rapidly and with enough strength to grab market share. Keeping market share can be easier than getting it. This market requires extensive advertising. Increasing market share could mean an increasing advertising budget. An increasing advertising budget can easily reduce profit margin, so strategic planning is required. The second way to solve the competition problem is in the formula itself. Management will seek to patent the formula. The nature of the homeopathic ingredients is likely to inhibit any mainstream non-homeopathic company from replicating the product. Acquisition of a homeopathic company would make more sense. Narrowing the competition, then, to other homeopathic companies gives Pain Away more of a fighting chance, since its formula is more sophisticated and user-friendly than any homeopathic topical analgesic on the market.
Governmental controls could conceivably impede sales. This problem is unlikely because the ingredients are already FDA-approved. Furthermore, management's participation in the FDA committee to develop regulatory standards for the natural medicine field would provide early warnings of any such prohibitory controls.
The company could be controlled by non-investor stockholders. This problem is not likely to develop because the management team would hold a majority. Management is dedicated to the principles of increasing value and profits and is confident that its efforts will be in concert with those of the investor.
Public offering.
Management plans for an IPO in 5-7 years. The investor's shares would be sold to provide the targeted return on investment. Should there be no public market, then a buy back would occur.
Management will negotiate a buy back formula with the investor and will target milestones in planning for this possibility. Management aims for returning 6 times the original investment in five years.
The business has not shown a profit since sales activity began in May 1994. This lack of profit is not unusual for an early-stage company. Losses were incurred in the start-up phase, where the objective was to get consumers to try the product. Gross profit margins have remained stable, however. Management focus was targeted on getting professionals and consumers to try the product in order to collect anecdotal evidence and testimonials of its effectiveness. Not enough focus was on asset management, as evidenced by a low return on assets ratio (p.32). Now that the product has gotten some recognition, especially in professional circles, the focus will shift toward mass marketing. Management intends to improve inventory management by using factoring of receivables in conjunction with JIT inventory control. As sales volume increases, drop-shipping from plant to wholesale customer, will also be arranged.
Cash | 690.89 | 1.21% |
Accounts Receivable | 10,119.48 | 17.76% |
Allowance for Bad Debt | −3,662.25 | −6.43% |
Deposits | 100.00 | 0.18% |
Inventory | 20,089.97 | 35.25% |
Prepaid Expenses | 13,339.06 | 23.41% |
40,677.15 | 71.38% | |
Furniture & Fixtures | 13,644.79 | 23.94% |
Total Prop & Equip | 13,644.79 | 23.94% |
Officers Loan Receivables | 100.00 | 0.18% |
Startup | 2,564.75 | 4.50% |
Total Other Assets | 2,664.75 | 4.68% |
Total Assets | 56,986.69 | 100.00% |
Accounts Payable | 77,960.80 | 136.81% |
Performance Plus | 47,937.46 | 84.12% |
PPI Ltd Partnership Payable | 24,281.73 | 42.61% |
Notes Payable Short-term | 7,000.00 | 12.28% |
Note Payable | 53,265.00 | 93.47% |
RSB Loan - Computer | 12,000.00 | 21.06% |
Note Payable - Officers | 1,809.93 | 3.18% |
Net Income (Loss) | (167,268.24) | −293.5% |
Sales | 20,194 | 46,942 | 53,320 | 49,955 | 46,701 | 33,865 |
Cost of Goods | 4,362 | 10,139 | 11,517 | 10,790 | 10,087 | 7,315 |
Gross Profit | 15,832 | 36,803 | 41,803 | 39,165 | 36,614 | 26,550 |
Selling Expenses | 15,549 | 36,078 | 29,754 | 36,564 | 30,178 | 10,381 |
General & Administrative | 12,483 | 19,051 | 22,784 | 28,488 | 27,851 | 27,821 |
28,032 | 55,129 | 525,538 | 65,052 | 58,029 | 38,202 | |
Net Income before Taxes | (12,200) | (18,326) | (10,735) | (25,887) | (21,415) | (11,652) |
Provision for Taxes | — | — | — | — | — | — |
Net Income after Taxes | (12,200) | (18,326) | (10,735) | (25,887) | (21,415) | (11,652) |
Gross Profit Percentage | 78.4% | 78.4% | 78.4% | 78.4% | 78.4% | 78.4% |
Cost of Goods as % of Sales | 21.6% | 21.6% | 21.6% | 21.6% | 21.6% | 21.6% |
Selling Expenses as % of Sales | 77.00% | 76.86% | 55.80% | 73.19% | 64.62% | 30.65% |
G&A as % of Sales | 61.82% | 40.58% | 42.73% | 57.03% | 59.64% | 82.15% |
Large | 711 | 1,652 | 1,877 | 2,215 | 2,070 | 1,501 |
Small | 627 | 1,457 | 1,656 | 1,071 | 1,001 | 726 |
1,338 | 3,109 | 3,533 | 3,286 | 3,071 | 2,227 |
Sales - cash/checks | 282,501.65 | 70.67% |
Sales - MC, Visa | 109,709.27 | 27.44% |
Sales - American Express | 8,371.88 | 2.09% |
Sales - Discover/Novus | 11,884.02 | 2.97% |
Discounts | (4,710.34) | −1.18% |
Returns | (7,468.74) | −1.87% |
Short/Over | (535.39) | −0.13% |
Total Revenues | 399,752.35 | 100.00% |
Cost of Goods | 66,453.96 | 16.62% |
Total Cost of Sales | 66,453.96 | 16.62% |
Gross Profit | 333,298.39 | 83.38% |
Expenses: | ||
Salaries - Sales | 59,734.52 | 14.94% |
Commissions - Sales | 18,754.35 | 4.69% |
Commissions - Outside sales | 69.93 | 0.02% |
Bonus - Sales | 3,218.75 | 0.81% |
Advertising | 46,721.87 | 11.69% |
Printing | 9,079.10 | 2.27% |
Brochures & Catalogs | 835.15 | 0.21% |
Trade Show | 10,501.98 | 2.63% |
Travel | 21,520.88 | 5.38% |
Entertainment | 777.22 | 0.19% |
Miscellaneous Sales Exp. | 1,811.78 | 0.45% |
Rent-Carts | 29,810.61 | 7.46% |
Salaries-Officers | 51,155.00 | 12.80% |
Salaries & Wages - Employees | 61,156.85 | 15.30% |
Payrol Tax Exp. | 20,816.36 | 5.21% |
Rent | 12,400.00 | 3.10% |
Utilities | 1,692.12 | 0.42% |
Insurance - General | 40.00 | 0.01% |
22,948 | 34,256 | 13,998 | 24,431 | 27,168 | 25,969 | 399,747 | 100.00% |
4,957 | 7,409 | 3,023 | 4,526 | 5,868 | (13,541) | 66,452 | 16.62% |
17,991 | 26,847 | 10,975 | 19,905 | 21,300 | 39,510 | 333,295 | 83.38% |
9,369 | 10,839 | 1,370 | 4,925 | 9,934 | 7,895 | 202,836 | 50.74% |
26,230 | 37,979 | 20,405 | 18,887 | 15,101 | 40,282 | 297,362 | 74.39% |
35,599 | 48,818 | 21,775 | 23,812 | 25,035 | 48,177 | 500,198 | 125.13% |
(17,608) | (21,971) | (10,800) | (3,907) | (3,735) | (8,667) | (166,903) | −41.75% |
— | — | — | 362 | 362 | |||
(17,608) | (21,971) | (10,800) | (3,907) | (3,735) | (9,029) | (167,265) | −41.84% |
78.4% | 78.4% | 78.4% | 81.5% | 78.4% | 152.1% | 83.4% | |
21.6% | 21.6% | 21.6% | 18.5% | 21.6% | −52.1% | 16.6% | |
40.83% | 31.64% | 9.79% | 20.16% | 36.57% | 30.40% | 50.74% | |
114.30% | 110.87% | 145.77% | 77.31% | 55.58% | 155.12% | 74.39% | |
1,302 | 1,410 | 775 | 871 | 871 | 871 | 16,126 | |
737 | 1,070 | 1,098 | 790 | 790 | 790 | 11,813 | |
2,039 | 2,480 | 1,873 | 1,661 | 1,661 | 1,661 | 27,939 |
Telephone | 36,265,64 | 9.07% |
Professional Fees | 6,241.95 | 1.56% |
Outside Services | 3,869.01 | 0.97% |
Management Fees | 24,441.68 | 6.11% |
UPS Exp. | 16,608.55 | 4.15% |
Postage Exp. | 10,116.10 | 2.53% |
Auto Exp. | 9,735.58 | 2.44% |
Equip. Rental/Leasing | 2,260.21 | 0.57% |
Office Exp. | 5,690.86 | 1.42% |
Supplies | 9,035.21 | 2.26% |
Contributions | 650.00 | 0.16% |
Dues & Subscriptions | 538.70 | 0.13% |
Repairs & Maintenance | 2,899.86 | 0.73% |
Bank Charges | 2,323.66 | 0.58% |
MC/Visa Service Chg. | 4,300.13 | 1.08% |
Amexco Service Chg. | 231.70 | 0.06% |
Discover Service Chg. | 275.05 | 0.07% |
Miscellanious | 1,035.90 | 0.26% |
Interest Expense | 10,141.79 | 2.54% |
Filing Fees | 10.00 | 0.00% |
Taxes - Other | 361.64 | 0.09% |
Travel & Entertainment | 119.87 | 0.03% |
Bad Debt Exp. | 3,231.10 | 0.82% |
Fines & Penalties | 93.92 | 0.02% |
Interest Income | (62.95) | −0.02% |
Total Current Assets | 40,677 | Current Ratio | Upper | Q2.2 | |
Total Current Liabilities | 157,180=Ratio | 026:1 | Median | 1.9 | |
Lower Q | 1.2 | ||||
Cash + A/R + N. Receivable | 10,810 | Quick Ratio | 1.6 | ||
Total Current Liabilities | 157,180=Ratio | 0.07:11 | 0.5 | ||
Net Fixed Assets | 13,645 | Fixed/Net Worth | 0.1 | ||
Tangible Net Worth | (167,268)=Ratio | −0.08:1 | 0.7 | ||
1.1 | |||||
Total Liabilities | 224,255 | Debt/Equity | 0.7 | ||
Tangible Net Worth | (167,268)=Ratio | −1.34:1 | 1.1 | ||
3.2 | |||||
Total Liabilities | 224,255 | Overall Leverage | |||
Total Assets | 56,987=Ratio | 3.94:1 | |||
Net Sales | 399,747 | Sales/Receivables | 32 | ||
Account & Notes Receivables | 10,119=Ratio | 39.50:1 | 40 | ||
39 | |||||
Days in Year, 365 | 365 | Day's Receivable | |||
Sales/Receivables Ratio | 39.50=Ratio | 9.24 days | |||
Cost of Sales | 66,454 | Inventory Turnover | |||
Inventory | 20,090=Ratio | 3.31x | |||
Days in Year, 365 | 365 | Days Inventory |
Cost of Goods/Inventory Ratio | 3.31 = Ratio | 110.34 days | |||
Net Sales | 399,747 | Sales to Working Capital | |||
Curr. Assets - Curr. Liabilities | (116,503) = Ratio | −3.43x | RMA Ratios | NA | |
Net Profit + Depr. + Amort. | (167,268) | Cash Flow/Long Term Debt | |||
Current Portion L T Debt | 7,000 = Ratio | −23.90x | |||
Profit, before Tax | (167,268) | Return on Equity | |||
Tangible Net Worth (Equity) | (167,268) = Ratio | 1.00% | |||
Profit, before Tax | (167,268) | Return on Assets | |||
THIS PORTION OF PAGE INTENTIONALLY LEFT BLANK SEE NEXT PAGE FOR PROJECTED CASH FLOW TABLE
*Factor fee 4% of sales. | ||||||
Cash On Hand | 700 | (78,316) | (38,066) | (5,092) | 46,819 | 178,117 |
Cash Receipts: | ||||||
Current month sales | 48,750 | 53,625 | 48,400 | 64,886 | 158,564 | 174,420 |
Prior accts receivables | 8,334 | 50,535 | 54,875 | 60,363 | 66,399 | 71,864 |
Investment proceeds | 0 | 0 | 0 | 0 | 0 | 0 |
Total Cash Receipts | 57,084 | 104,160 | 103,275 | 125,249 | 224,963 | 246,284 |
Cash Available | 57,784 | 25,844 | 65,209 | 120,157 | 271,781 | 424,401 |
Cash disbursements: | ||||||
Cost of product | 10,800 | 11,880 | 13,068 | 14,375 | 15,552 | 16,200 |
Advertising | 6,000 | 6,600 | 7,260 | 7,986 | 8,640 | 9,000 |
Promotions | 0 | 0 | 0 | 10,000 | 10,000 | 10,000 |
Selling expenses | 8,300 | 9,130 | 10,043 | 11,047 | 11,952 | 12,450 |
General & admin | 33,000 | 36,300 | 39,930 | 39,930 | 47,520 | 49,500 |
Research & Development | 0 | 0 | 0 | 0 | 0 | 20,000 |
Income taxes | 0 | 0 | 0 | 0 | 0 | 36,000 |
Prior accounts payable | 78,000 | — | — | — | — | — |
Total Disbursements | 136,100 | 63,910 | 70,301 | 73,338 | 93,664 | 153,150 |
Cash End of Month | (78,316) | (38,066) | (5,092) | 46,819 | 178,117 | 271,251 |
Operating Data | ||||||
Sales per Month | 50,000 | 55,000 | 60,500 | 66,550 | 72,000 | 75,000 |
Cost of Goods | 10,800 | 11,880 | 13,068 | 11,979 | 12,960 | 13,500 |
Curr Mth collections | 48,750 | 53,625 | 58,988 | 64,886 | 70,200 | 73,125 |
Factor Fees* | 0 | 0 | 0 | 0 | 0 | 0 |
Collection of A/R |
Sales | 2,730 | 8,000 | 18,000 | 32,000 | 50,000 |
Cost of Goods sold | 497 | 1,440 | 3,240 | 5,760 | 9,000 |
Gross Profit | 2,233 | 6,560 | 14,760 | 26,240 | 41,000 |
Advertising | 986 | 2,000 | 4,500 | 8,000 | 12,500 |
Selling Expenses | 345 | 960 | 2,160 | 3,840 | 6,000 |
General & Administrative | 669 | 1,440 | 3,240 | 5,760 | 9,000 |
Total Opr Expenses | 2,000 | 4,400 | 9,900 | 17,600 | 27,500 |
Net Income Before Taxes | 233 | 2,160 | 4,860 | 8,640 | 13,500 |
Provision for Taxes | 93 | 864 | 1,944 | 3,456 | 5,400 |
Net Income After Taxes | 140 | 1,296 | 2,916 | 5,184 | 8,100 |
Dividend Distributions | 70 | 648 | 1,458 | 2,592 | 4,050 |
Retained Earnings | 70 | 648 | 1,458 | 2,592 | 4,050 |
% Cost of Goods Sold | 18% |
% Selling Expenses | 12% |
% General & Administrative | 18% |
% Tax Provision | 40% |
Dividends - of NATP | 50% |
Advertising -1996 | 40% |
Advertising - all other years | 25% |
271,251 | 1,735,989 | 1,747,574 | 1,736,317 | 1,761,974 | 1,790,876 | 1,788,843 |
191,862 | 211,049 | 320,154 | 349,288 | 381,073 | 427,951 | 2,430,022 |
0 | 38,372 | 42,210 | 64,031 | 69,857 | 76,215 | 603,054 |
1,500,000 | 1,500,000 | |||||
1,691,862 | 249,421 | 362,364 | 413,319 | 450,930 | 504,166 | 4,533,076 |
1,963,113 | 1,985,410 | 2,109,938 | 2,149,636 | 2,212,905 | 2,295,042 | 6,321,919 |
39,245 | 43,169 | 47,486 | 72,035 | 78,590 | 85,741 | 448,141 |
95,931 | 105,524 | 160,077 | 174,644 | 190,536 | 213,976 | 986,174 |
10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 80,000 |
28,779 | 31,657 | 48,023 | 52,393 | 57,161 | 64,193 | 345,128 |
43,169 | 47,486 | 72,035 | 78,590 | 85,741 | 96,289 | 669,490 |
10,000 | 0 | 0 | 0 | 0 | 0 | 30,000 |
0 | 0 | 36,000 | 0 | 0 | 36,000 | 108,000 |
— | — | — | — | — | — | 78,000 |
227,124 | 237,836 | 373,621 | 387,662 | 422,028 | 506,199 | 2,744,933 |
1,735,989 | 1,747,574 | 1,736,317 | 1,761,974 | 1,790,876 | 1,788,843 | 3,576,986 |
239,828 | 263,811 | 400,192 | 436,609 | 476,341 | 534,939 | 2,730,770 |
43,169 | 47,486 | 72,035 | 78,590 | 85,741 | 96,289 | 497,497 |
191,862 | 211,049 | 320,154 | 349,287 | 381,073 | 427,951 | 2,250,950 |
9,593 | 10,552 | 16,008 | 17,464 | 19,054 | 21,398 | 109,231 |
38,372 | 42,210 | 64,031 | 69,857 | 76,215 | 85,590 |
Comment about this article, ask questions, or add new information about this topic:.
In the fast-paced world of pharmaceuticals, having a strategic plan is essential to stay ahead of the competition and drive success. ClickUp's Pharmaceutical Company Strategic Plan Template is designed to help executive leadership teams outline their long-term goals and objectives with ease.
This comprehensive template allows you to:
With ClickUp's Strategic Plan Template, you can streamline your planning process, align your team, and confidently navigate the ever-evolving pharmaceutical landscape. Take the first step towards success today!
When using the Pharmaceutical Company Strategic Plan Template, you can expect to experience several benefits that will help drive the success and growth of your company:
ClickUp's Pharmaceutical Company Strategic Plan template equips your team with the tools needed to effectively plan and execute strategic initiatives in the pharmaceutical industry.
Here are the main elements of this template:
Creating a strategic plan for your pharmaceutical company is essential for long-term success. Follow these steps to effectively use the Pharmaceutical Company Strategic Plan Template in ClickUp:
Start by clearly defining the mission and vision of your pharmaceutical company. What is the purpose of your organization and what do you hope to achieve in the future? This will guide all of your strategic planning efforts.
Use a Doc in ClickUp to write down your mission and vision statements and ensure alignment within your team.
Assess the strengths, weaknesses, opportunities, and threats of your pharmaceutical company. Identify the internal strengths and weaknesses of your organization, as well as the external opportunities and threats in the industry. This analysis will help you understand your competitive advantage and areas for improvement.
Create custom fields in ClickUp to track each element of your SWOT analysis and ensure it's easily accessible for reference.
Based on the findings from your SWOT analysis, set strategic goals for your pharmaceutical company. These goals should be specific, measurable, achievable, relevant, and time-bound (SMART), and aligned with your mission and vision. Examples of strategic goals could include expanding into new markets, developing new drugs, or improving operational efficiency.
Use Goals in ClickUp to create and track your strategic goals, assign them to team members, and set deadlines for completion.
Once your strategic goals are set, develop action plans to achieve them. Break down each goal into actionable steps, assign responsibilities to team members, and set deadlines. This will ensure that everyone is clear on what needs to be done and when.
Use tasks in ClickUp to create action plans for each strategic goal, assign them to team members, and set due dates and reminders.
Regularly monitor the progress of your strategic plan and make adjustments as needed. Track key performance indicators (KPIs) to measure the success of your initiatives and identify areas that require improvement. If certain strategies are not yielding the desired results, be open to making changes and adapting your plan accordingly.
Use Dashboards in ClickUp to track and visualize your KPIs, monitor progress, and easily identify areas that need attention or adjustment.
By following these steps and utilizing the Pharmaceutical Company Strategic Plan Template in ClickUp, you'll be able to develop a comprehensive and effective strategic plan for your pharmaceutical company.
The executive leadership team of a pharmaceutical company can use this Pharmaceutical Company Strategic Plan Template to align their long-term goals and objectives and drive the overall success and growth of the company.
First, hit “Add Template” to sign up for ClickUp and add the template to your Workspace. Make sure you designate which Space or location in your Workspace you’d like this template applied.
Next, invite relevant members or guests to your Workspace to start collaborating.
Now you can take advantage of the full potential of this template to create a comprehensive strategic plan:
Free forever with 100mb storage.
Free training & 24-hours support
Serious about security & privacy
Highest levels of uptime the last 12 months
Writing a business plan for a pharmaceutical wholesaler can be an intimidating task, especially for those just starting.
This in-depth guide is designed to help entrepreneurs like you understand how to create a comprehensive business plan so that you can approach the exercise with method and confidence.
We'll cover: why writing a pharmaceutical wholesaler business plan is so important - both when starting up, and when running and growing the business - what information you need to include in your plan, how it should be structured, and what tools you can use to get the job done efficiently.
Let's get started!
In this guide:
Being clear on the scope and goals of the document will make it easier to understand its structure and content. So before diving into the actual content of the plan, let's have a quick look at the main reasons why you would want to write a pharmaceutical wholesaler business plan in the first place.
Small businesses rarely experience a constant and predictable environment. Economic cycles go up and down, while the business landscape is mutating constantly with new regulations, technologies, competitors, and consumer behaviours emerging when we least expect it.
In this dynamic context, it's essential to have a clear roadmap for your pharmaceutical wholesaler. Otherwise, you are navigating in the dark which is dangerous given that - as a business owner - your capital is at risk.
That's why crafting a well-thought-out business plan is crucial to ensure the long-term success and sustainability of your venture.
To create an effective business plan, you'll need to take a step-by-step approach. First, you'll have to assess your current position (if you're already in business), and then identify where you'd like your pharmaceutical wholesaler to be in the next three to five years.
Once you have a clear destination for your pharmaceutical wholesaler, you'll focus on three key areas:
By going through this process regularly, you'll be able to make informed decisions about resource allocation, paving the way for the long-term success of your business.
Need a convincing business plan?
The Business Plan Shop makes it easy to create a financial forecast to assess the potential profitability of your projects, and write a business plan that’ll wow investors.
If your small pharmaceutical wholesaler runs out of cash: it's game over. That's why we often say "cash is king", and it's crucial to have a clear view of your pharmaceutical wholesaler's future cash flows.
So, how can you achieve this? It's simple - you need to have an up-to-date financial forecast.
The good news is that your pharmaceutical wholesaler business plan already includes a financial forecast (which we'll discuss further in this guide). Your task is to ensure it stays current.
To accomplish this, it's essential to regularly compare your actual financial performance with what was planned in your financial forecast. Based on your business's current trajectory, you can make adjustments to the forecast.
By diligently monitoring your pharmaceutical wholesaler's financial health, you'll be able to spot potential financial issues, like unexpected cash shortfalls, early on and take corrective actions. Moreover, this practice will enable you to recognize and capitalize on growth opportunities, such as excess cash flow enabling you to expand to new locations.
Crafting a comprehensive business plan for your pharmaceutical wholesaler, whether you're starting up or already established, is paramount when you're seeking financing from banks or investors.
Given how fragile small businesses are, financiers will want to ensure that you have a clear roadmap in place as well as command and control of your future cash flows before entertaining the idea of funding you.
For banks, the information in your business plan will be used to assess your borrowing capacity - which is defined as the maximum amount of debt your business can afford alongside your ability to repay the loan. This evaluation helps them decide whether to extend credit to your business and under what terms (interest rate, duration, repayment options, collateral, etc.).
Similarly, investors will thoroughly review your plan to determine if their investment can yield an attractive return. They'll be looking for evidence that your pharmaceutical wholesaler has the potential for healthy growth, profitability, and consistent cash flow generation over time.
Now that you understand the importance of creating a business plan for your pharmaceutical wholesaler, let's delve into the necessary information needed to craft an effective plan.
Drafting a pharmaceutical wholesaler business plan requires research so that you can project sales, investments and cost accurately in your financial forecast, and convince the reader that there is a viable commercial opportunity to be seized.
Below, we'll focus on three critical pieces of information you should gather before starting to write your plan.
Carrying out market research before writing a business plan for a pharmaceutical wholesaler is essential to ensure that the financial projections are accurate and realistic.
Market research helps you gain insight into your target customer base, competitors, pricing strategies and other key factors which can have an impact on the commercial success of your business.
In particular, it is useful in forecasting revenue as it provides valuable data regarding potential customers’ spending habits and preferences.
Your market research might reveal that wholesalers may be shifting away from traditional sales channels to more digital ones, such as online or automated ordering systems. Additionally, research may demonstrate that wholesalers may be increasingly seeking out partnerships with third-party logistics providers for more cost-effective and efficient distribution services.
This information can then be used to create more accurate financial projections which will help investors make informed decisions about investing in your pharmaceutical wholesaler.
As you embark on creating your pharmaceutical wholesaler business plan, it is crucial to budget sales and marketing expenses beforehand.
A well-defined sales and marketing plan should include precise projections of the actions required to acquire and retain customers. It will also outline the necessary workforce to execute these initiatives and the budget required for promotions, advertising, and other marketing efforts.
This approach ensures that the appropriate amount of resources is allocated to these activities, aligning with the sales and growth objectives outlined in your business plan.
As you embark on starting or expanding your pharmaceutical wholesaler, having a clear plan for recruitment and capital expenditures (investment in equipment and real estate) is essential for ensuring your business's success.
Both the recruitment and investment plans must align with the timing and level of growth projected in your forecast, and they require appropriate funding.
A pharmaceutical wholesaler might incur staffing costs such as salaries, benefits, and training for employees. They might also incur equipment costs, such as purchasing and maintaining computers and other technology, and purchasing and maintaining delivery vehicles.
To create a realistic financial forecast, you also need to consider other operating expenses associated with the day-to-day running of your business, such as insurance and bookkeeping.
With all the necessary information at hand, you are ready to begin crafting your business plan and developing your financial forecast.
The objective of the financial forecast of your pharmaceutical wholesaler's business plan is to show the growth, profitability, funding requirements, and cash generation potential of your business over the next 3 to 5 years.
The four key outputs of a financial forecast for a pharmaceutical wholesaler are:
Let's look at each of these in a bit more detail.
The projected P&L statement for a pharmaceutical wholesaler shows how much revenue and profits your business is expected to generate in the future.
Ideally, your pharmaceutical wholesaler's P&L statement should show:
Expectations will vary based on the stage of your business. A startup will be expected to grow faster than an established pharmaceutical wholesaler. And similarly, an established company should showcase a higher level of profitability than a new venture.
The balance sheet for a pharmaceutical wholesaler is a financial document that provides a snapshot of your business’s financial health at a given point in time.
It shows three main components: assets, liabilities and equity:
Examining the balance sheet is important for lenders, investors, or other stakeholders who are interested in assessing your pharmaceutical wholesaler's liquidity and solvency:
Looking at the balance sheet can also provide insights into your pharmaceutical wholesaler's investment and financing policies.
In particular, stakeholders can compare the value of equity to the value of the outstanding financial debt to assess how the business is funded and what level of financial risk has been taken by the owners (financial debt is riskier because it has to be repaid, while equity doesn't need to be repaid).
A projected cash flow statement for a pharmaceutical wholesaler is used to show how much cash the business is generating or consuming.
The cash flow forecast is usually organized by nature to show three key metrics:
As we discussed earlier, cash is king and keeping an eye on future cash flows an imperative for running a successful business. Therefore, you can expect the reader of your pharmaceutical wholesaler business plan to pay close attention to your cash flow forecast.
Also, note that it is customary to provide both yearly and monthly cash flow forecasts in a business plan - so that the reader can analyze seasonal variation and ensure the pharmaceutical wholesaler is appropriately funded.
The sources and uses table or initial financing plan is a key component of your business plan when starting a pharmaceutical wholesaler.
It shows where the capital needed to set up the business will come from (sources) and how it will be spent (uses).
This table helps size the investment required to set up the pharmaceutical wholesaler, and understand how risks will be distributed between the business owners, and the financiers.
The sources and uses table also highlights what the starting cash position will be. This is key for startups as the business needs to have sufficient funding to sustain operations until the break-even point is reached.
Now that you have a clear understanding of what will go into the financial forecast of your pharmaceutical wholesaler business plan, let's have a look at the written part of the plan.
The written part of a pharmaceutical wholesaler business plan plays a key role: it lays out the plan of action you intend to execute to seize the commercial opportunity you've identified on the market and provides the context needed for the reader to decide if they believe your plan to be achievable and your financial forecast to be realistic.
The written part of a pharmaceutical wholesaler business plan is composed of 7 main sections:
Let's go through the content of each section in more detail!
The executive summary, the first section of your pharmaceutical wholesaler's business plan, serves as an inviting snapshot of your entire plan, leaving readers eager to know more about your business.
To compose an effective executive summary, start with a concise introduction of your business, covering its name, concept, location, history, and unique aspects. Share insights about the services or products you intend to offer and your target customer base.
Subsequently, provide an overview of your pharmaceutical wholesaler's addressable market, highlighting current trends and potential growth opportunities.
Then, present a summary of critical financial figures, such as projected revenues, profits, and cash flows.
You should then include a summary of your key financial figures such as projected revenues, profits, and cash flows.
Lastly, address any funding needs in the "ask" section of your executive summary.
The second section in your pharmaceutical wholesaler's business plan should focus on the structure and ownership, location, and management team of the company.
The structure and ownership part provides an overview of the legal structure of the business, who the owners are and how much each has invested and owns. If you are seeking financing it is important that the reader gets a clear picture of which legal entity is receiving the funds, and who controls the business.
The location part should give an overview of the premises from which the company is operating, and why that location is of particular interest (catchment area, accessibility, amenities nearby, etc.).
When describing the location of your pharmaceutical wholesaler, you may want to emphasize its access to major transportation routes, its proximity to a major metropolitan area, and its potential for growth. The area could offer multiple options for shipping and receiving, such as airports, railroads, and highways. It could also be in close proximity to a large city, allowing for easy access to customers and suppliers. The potential for growth in the area could create opportunities for the wholesaler to expand its operations, increase its customer base, and capitalize on new markets. All of these factors could make the location an attractive choice for a third party financier.
Finally, you should introduce the management team. Explain each member's role, background, and experience.
It is also important to emphasize any past successes that the members of the management team have achieved, and how long they've been working together, as this will help potential lenders or investors understand why they should trust in their leadership.
The products and services section of your business plan should include a detailed description of what your company offers, who are the target customers, and what distribution channels are part of your go-to-market.
For example, your pharmaceutical wholesaler might offer a wide range of products and services, such as delivering quality healthcare products, providing access to competitive pricing, and offering a customized inventory management system. This helps customers get the supplies they need quickly and efficiently with minimal disruption to their operations. Additionally, many pharmaceutical wholesalers offer a variety of value-added services, such as providing advice on regulatory issues, facilitating bulk ordering, and offering online ordering options. These services help customers get the most out of their investment in pharmaceuticals, while also ensuring that they are compliant with applicable regulations.
When you present your market analysis in your pharmaceutical wholesaler business plan, it's crucial to include detailed information about customers' demographics and segmentation, target market, competition, barriers to entry, and any relevant regulations.
The main objective of this section is to help the reader understand the size and attractiveness of the market while demonstrating your solid understanding of the industry.
Begin with the demographics and segmentation subsection, providing an overview of the addressable market for your pharmaceutical wholesaler, the key trends in the marketplace, and introducing different customer segments along with their preferences in terms of purchasing habits and budgets.
Next, focus on your target market, zooming in on the specific customer segments your pharmaceutical wholesaler aims to serve and explaining how your products and services fulfil their distinct needs.
For example, your target market might include hospitals and large medical facilities. These customers would purchase large quantities of pharmaceuticals often, making them the ideal target for a pharmaceutical wholesaler. Additionally, these customers would need to work with a reliable supplier to ensure that they have the medications they need when they need them.
Then proceed to the competition subsection, where you introduce your main competitors and highlight what sets you apart from them.
Finally, conclude your market analysis with an overview of the key regulations applicable to your pharmaceutical wholesaler.
When you write the strategy section of your pharmaceutical wholesaler business plan, remember to cover key elements such as your competitive edge, pricing strategy, sales & marketing plan, milestones, and risks and mitigants.
In the competitive edge subsection, elaborate on what makes your company stand out from competitors. This becomes especially important if you're a startup, aiming to carve a place for yourself amidst established players in the marketplace.
The pricing strategy subsection should demonstrate how you plan to maintain profitability while offering competitive prices to attract customers.
Outline your sales & marketing plan, detailing how you'll reach out to new customers and retain existing ones through loyalty programs or special offers.
For the milestones subsection, outline your company's achievements to date and your main objectives for the future, complete with specific dates to set clear expectations for progress.
Lastly, the risks and mitigants subsection should address the main risks that could affect your plan's execution. Explain the measures you've put in place to minimize these risks, assuring potential investors or lenders.
Your pharmaceutical wholesaler could face the risk of theft. This could occur both internally, if employees attempt to steal medications, as well as externally, if criminals attempt to break into the warehouse and steal medications. Your pharmaceutical wholesaler may also face the risk of financial losses due to the cost of purchasing medications and the possibility of not being able to sell them in a timely fashion. In addition, changes in regulation or the cost of medications could also lead to financial losses.
In your business plan, it's also essential to provide a detailed overview of the operations of your pharmaceutical wholesaler.
Start by covering your team, highlighting key roles and your recruitment plan to support the expected growth. Outline the qualifications and experience required for each role and your intended recruitment methods, whether through job boards, referrals, or headhunters.
Next, clearly state your pharmaceutical wholesaler's operating hours, allowing the reader to assess staffing levels adequately. Additionally, mention any plans for varying opening times during peak seasons and how you'll handle customer queries outside normal operating hours.
Then, shift your focus to the key assets and intellectual property (IP) necessary for your business. If you rely on licenses, trademarks, physical structures like equipment or property, or lease agreements, make sure to include them in this section.
You may have key assets such as inventory and customer data that could be considered intellectual property (IP). These assets could be protected by copyright laws and other regulations. Additionally, the wholesaler might also have trade secrets such as supplier relationships, pricing information, and product formulations that could be protected as IP.
Lastly, include a list of suppliers you plan to work with, detailing their services and main commercial terms, such as price, payment terms, and contract duration. Investors are interested in understanding why you've chosen specific suppliers, which may be due to higher-quality products or established relationships from previous ventures.
The financial plan section is where we will include the financial forecast we talked about earlier in this guide.
Now that you have a clear idea of the content of a pharmaceutical wholesaler business plan, let's look at some of the tools you can use to create yours.
In this section, we will be reviewing the two main options for writing a pharmaceutical wholesaler business plan efficiently:
Using online business planning software is the most efficient and modern way to create a pharmaceutical wholesaler business plan.
There are several advantages to using specialized software:
If you're interested in using this type of solution, you can try The Business Plan Shop for free by signing up here .
Outsourcing your pharmaceutical wholesaler business plan to a business plan writer can also be a viable option.
Business plan writers are experienced in writing business plans and adept at creating financial forecasts without errors. Furthermore, hiring a consultant can save you time and allow you to focus on the day-to-day operations of your business.
However, hiring business plan writers is expensive as you are paying for the software used by the consultant, plus their time, and their profit margin of course.
From experience, you need to budget at least £1.5k ($2.0k) excluding tax for a complete business plan, more if you need to make changes after the initial version (which happens frequently after the initial meetings with lenders or investors).
You also need to be careful when seeking investment. Investors want their money to be used to grow the business, not spent on consulting fees. Therefore, the amount you spend on business plan writing services (and other consulting services such as legal services) needs to be negligible relative to the amount raised.
The other drawback is that you usually don't own the business plan itself: you just get the output, while the actual document is saved in the consultant's business plan software - which makes it difficult to maintain the document up to date without hiring the consultant on a retainer.
For these reasons, outsourcing the pharmaceutical wholesaler business plan to a business plan writer should be considered carefully, weighing both the advantages and disadvantages of hiring outside help.
Ultimately, it may be the right decision for some businesses, while others may find it beneficial to write their business plan using online software.
Using Microsoft Excel and Word (or their Google, Apple, or open-source equivalents) to write a pharmaceutical wholesaler business plan is a terrible idea.
For starters, creating an accurate and error-free financial forecast on Excel (or any spreadsheet) is very technical and requires both a strong grasp of accounting principles and solid skills in financial modelling.
As a result, it is unlikely anyone will trust your numbers unless - like us at The Business Plan Shop - you hold a degree in finance and accounting and have significant financial modelling experience in your past.
The second reason is that it is inefficient. Building forecasts on spreadsheets was the only option in the 1990s and early 2000s, nowadays technology has advanced and software can do it much faster and much more accurately.
And with the rise of AI, software is also becoming smarter at helping us detect mistakes in our forecasts and helping us analyse the numbers to make better decisions.
Also, using software makes it easy to compare actuals vs. forecasts and maintain our forecasts up to date to maintain visibility on future cash flows - as we discussed earlier in this guide - whereas this is a pain to do with a spreadsheet.
That's for the forecast, but what about the written part of my pharmaceutical wholesaler business plan?
This part is less error-prone, but here also software brings tremendous gains in productivity:
Overall, while Word or Excel may be viable options for creating a pharmaceutical wholesaler business plan for some entrepreneurs, it is by far not the best or most efficient solution.
We hope that this practical guide gave you insights on how to write the business plan for your pharmaceutical wholesaler. Do not hesitate to get in touch with our team if you still have questions.
Know someone who owns or wants to start a pharmaceutical wholesaler? Share this article with them!
Founder & CEO at The Business Plan Shop Ltd
Guillaume Le Brouster is a seasoned entrepreneur and financier.
Guillaume has been an entrepreneur for more than a decade and has first-hand experience of starting, running, and growing a successful business.
Prior to being a business owner, Guillaume worked in investment banking and private equity, where he spent most of his time creating complex financial forecasts, writing business plans, and analysing financial statements to make financing and investment decisions.
Guillaume holds a Master's Degree in Finance from ESCP Business School and a Bachelor of Science in Business & Management from Paris Dauphine University.
Create a convincing business plan
Assess the profitability of your business idea and create a persuasive business plan to pitch to investors
500,000+ entrepreneurs have already tried our solution - why not join them?
Not ready to try our on-line tool? Learn more about our solution here
Need some inspiration for your business plan?
Subscribe to The Business Plan Shop and gain access to our business plan template library.
Need a professional business plan? Discover our solution
Write your business plan with ease!
It's easy to create a professional business plan with The Business Plan Shop
Want to find out more before you try? Learn more about our solution here
A Pharmaceutical or drug company is a part of the healthcare sector and involved in a commercial licensed business of research & development, manufacturing, marketing, and distributing drugs and medications. Different laws and regulations are imposed on the pharmaceutical companies related to patent, drug testing and marketing, drug safety, pricing and quality of drugs, etc. The pharmaceutical industry includes both private and public pharmaceutical companies that play an important role in vaccine and medication development for the purpose of preventing and reducing diseases. Enhancing quality of life by making a significant contribution in innovative research and active engagement in technological advancements so that the complex healthcare demands of people can be fulfilled; also comes under the portfolio of Pharmaceutical companies. The main aim of the industry is to make sure the availability of drugs for maintaining health by preventing and curing infectious diseases that affect a large population. The pharmaceutical companies are further classified into subcategories based upon their functioning i.e. biotechnology companies, drug manufacturing companies, and the wholesale & distribution companies that are responsible for handling the produced products. As per IBEF (India Brand Equity Foundation), India is considered as the largest providers in generic drugs category all over the world. The Pharmaceutical companies of India supply various vaccines i.e. more than 50% of global demand. Recently, on the demand of International countries that are most affected countries due to Covid-19 such as U.S., Russia, Sri Lanka, etc; India has supplied Hydroxychloroquine tablets to these countries for the treatment of the disease as India is one of the largest producers of these tablets all around the world.
The history of Pharmaceutical companies and the use of drugs or medicines are quite old from the Medieval Ages where the records are found of people making use of herbs and other plants for healing. We can trace the concept of the modern pharmaceutical industry by the discovery of penicillin and insulin drugs in the 20 th century. Different developed countries, especially European countries, started manufacturing these drugs on a mass production basis. Arabian Pharmacists of Baghdad opened the first drugstore in 754. Lots of drugstores in North America and Europe were converted or developed into big pharmaceutical companies in the 19 th century. 19 th and 20 th centuries became a witness for the discovery of major pharmaceutical companies that exist today.
A business model can be viewed as a framework that considers the technological characteristics and potentials of the company as inputs which are built on key resources, key partners and key activities of the company; and further converts these inputs into valuable economic output through the customer relationship, target customer segments, and key distribution channels by means of product or service offering i.e. value proposition. Before going into the detail of each element of the business Model of Pharmaceutical companies, let’s understand first different business segments of Pharmaceutical companies and how they work:
1) API (Active Pharmaceutical Ingredient): To understand the business model of pharmaceutical companies, it is worth taking an idea of the important ingredient in the Pharma industry i.e. API which is considered as the main active ingredient in the drug or medicine to cure diseases. The raw material that is being used to produce medicines, also termed as bulk drugs or API. Various pharmaceutical companies are there that are specialists in producing only APIs. These companies either purchase or produce intermediates themselves for making the final API. Further, these companies sell APIs to different formulation companies for producing final medical drug/medicine. One of such API pharmaceutical companies is Lupin Pharma.
2) Formulations: The term pharmaceutical formulation refers to the process of producing the final medical drug or medicine by combining various chemical substances, including the APIs. In the process of medicine manufacturing, formulations are the end result or product and are available in the form of capsules, tablets, syrups, or injectables.
The pharmaceutical companies indulge in manufacturing of formulations are considered as formulation pharma companies like Dr. Reddy’s Laboratories. Pharmaceutical formulations are of two types i.e.
3) CRAMS (Contract Research and Manufacturing): CRAMS stands for Contract Research and Manufacturing service which is considered as a process by which pharmaceutical companies outsource their research services or activities related to product manufacturing to the companies which offer low- cost services. Basically, two main activities i.e. Contract Research and Contract Manufacturing come under CRAMS. Pharmaceutical and Biotechnology companies that need extensive Research & Development and manufacturing facilities at large-scale, use CRAMS. This segment of the Pharmaceutical and Biotech industry is also growing at a fast rate. Most of the pharma companies are increasing their outsourcing activities due to the extreme pressure of maintaining fixed costs.
4) Export/Import Business segment: The Pharmaceutical sector of India is considered as the largest supplier of generic medicines to the developed countries and these medicines are cost-effective too. India exports drugs/ medicines over 200 countries around the globe and the U.S. is the key market for exports. India has witnessed US $19.14 billion pharmaceutical exports in FY19 and US $13.69 exports were there up to January 2020. The exports of pharmaceutical companies consist of drug formulations, bulk drugs, biological, surgical, intermediates, Ayush & herbal products, etc.
5) Pipelines in Biotech Companies: Pipeline in pharmaceutical companies, especially in biotech companies refers to the different phases of clinical trials of drug medicine. In the pharmaceutical sector, this term is often used while defining and evaluating the activities, R&D (Research & Development) progress, measuring success, and growth potential for biotechnology pharmaceutical companies. When the status of a drug is considered in the pipeline; it means different clinical trial stages in which it is undergoing or have to undergo before getting approval for final use in the market. So, we can say that different drug medicines that are into clinical trial phases and seeking approval of USFDA (U.S. Food and Drug Administration Authority) are considered as pipeline drugs.
The various stages of a drug clinical trial are as under:
6) Biotech: Pharmaceutical companies are inter-linked with biotechnology companies in terms of obtaining licenses from them for the manufacturing of patented products. Different segments of the Biotechnology sector of India are Bio-Agriculture, Bio-Pharmaceutical, Bio-Services, Bio-Informatics, and Bio-Industrial. Biopharmaceutical products which are mostly pharmaceuticals, also referred to as biological medical product which is a pharmaceutical drug product, manufactured and extracted from biological sources. This includes allergenic, vaccines, tissues, living medicines that are being used for cell therapy, etc.
7 ) Drug marketing: One of the important business segments of Pharmaceutical companies is marketing. Pharmaceutical companies enhance their market reach with the support of marketing companies or in-house marketing team. Drug marketing companies facilitate these companies by selling their products where pharmaceutical manufacturing companies are not able to sell products in a particular area or region due to the absence of necessary license or marketing network. Now, after gaining insights into the business segments of Pharmaceutical companies, let’s review the different current and emerging business models of the companies:
A) Block Business Model
In traditional terms, the pharmaceutical industry’s current business model is made around the blockbuster drugs and is referred to as the Blockbuster business model. The mass market is the main target of this business model with an expectation to bring revenue from high sales. Any drug that generates annual sales of over US$1 billion then it is said as a blockbuster. The main uses of these drugs are for the treatment of common medical issues such as diabetes, asthma, high blood pressure, cancer, and high cholesterol, etc. The blockbuster business model of pharmaceutical companies is related to investing a significant budget into in-house R&D (Research & Development) activities, to search different dead-end projects with the hope of turning a few of them into the successful blockbusters that generate high returns.
Blockbuster business Model Canvas of Pharmaceutical Companies
Different elements mentioned in the above Blockbuster business model canvas of Pharmaceutical Companies are as under:
The target customers of pharmaceutical companies under the blockbuster business model are mainly doctors and patients as the companies cover a mass market. Moreover, various health institutions like hospitals, clinics, pharmacies, etc. also come under customer segment portfolio.
Pharmaceutical companies generally have the following key partners:
Pharmaceutical companies that operate on Blockbuster business model have various key activities such as Research & Development with the companies rather than outsourcing, Development and production or manufacturing of various drugs/ medicines and healthcare products, Testing of drugs, marketing and distribution of drugs to appropriate customer segments using various marketing and distribution channels, and managing internal personnel, production, costing, etc.
The main resources of pharmaceutical companies include research & development platform, technology (Artificial intelligence and Machine learning), technical and non-technical staff, intellectual property, generic capabilities (use of today’s drug innovation for future innovations i.e. both production and innovation), etc.
Various medium or channels of pharmaceutical companies include:
Pharmaceutical companies enhance and maintain their customer relationship by providing various customer assistance and customer support facilities such as :
The revenue model of pharmaceutical companies is clubbed in the below chart:
As of April 2020
*(Information Source: Statista.com)
Pharmaceutical companies bear different expenses in the development and sale of products & services such as:
The pharmaceutical companies working on the Blockbuster business model are facing the biggest challenge i.e. expiry of the patent of the blockbuster drugs and a great expansion of generic drugs. Apart from the expiry of patent, other challenges in front of these companies are of deficiency of new product innovations and high cost-margins. This resulted in the diversification of innovative drug manufacturing companies into generic drug manufacturing. The current blockbuster business model of pharmaceutical companies is moving slowly into a focused and lean type business model which is made of small and local R&D clusters. Wherein, the earlier blockbuster business model is focused on more diversified global R&D clusters. So future pharmaceutical companies demand more specialized and defragmented business model with a focus on core capabilities to sustain long-term growth.
The future of the pharmaceutical industry seeks improvement in R&D productivity, cost reduction, to grasp the opportunities of emerging economies, etc. The futuristic approach will even look forward of the collaboration of large pharmaceutical companies with others for the development of more economical and effective new medicines, support patients for health management, and for ensuring the true impact of products and services offered by them. Mainly, 2 emerging business model i.e. Federated and Fully Diversified will support in future prospects of Pharmaceutical companies.
Let’s have a look at these emerging Business models of Pharmaceutical companies:
A) Federated Business Model:
The federated approach includes network creation of separate identities by the companies that consist of a common platform of supporting infrastructure. The different participant companies have a common goal like managing outcomes in the available population of patients. Companies are interdependent with each other as they share data, funds, back-office services, and patient access. This model facilitates a framework for developing a product’s integrated packages and so, it diversifies beyond the core offering of a pharmaceutical company. Each participant in this model is enabled to make a particular segment of expertise, to have a competitive advantage as an outcome of expertise, and to sell its offerings i.e. products or skills, by transferring those activities that are better disbursed by other partner firms of the federation. The federated business model is further categorized into two categories i.e.:
1.a) Federated model’s virtual variant
In this type of federated business model, the pharmaceutical companies outsource almost all of its operations and the company reflects as a management hub that coordinates the various activities of partners. Several large pharmaceutical companies are already working on this model up to some extent. These pharmaceutical companies acquire external contractors to fulfill their own resources. By outsourcing various activities i.e. manufacturing, marketing & promotional activities, R&D, etc. to 3 rd parties, they can take advantage of specialist skills, wider scope of opportunities, and market access. Doing so, these companies can further focus on other value-addition activities like business development, project management, management of intellectual property, regulatory affairs, etc.
1.b) Federated model’s venture variant
This vertical of federated business model demands an investment in a portfolio of pharmaceutical companies and in return to have a share of capital growth or the intellectual assets, instead of outsourcing specific activities. Pharmaceutical companies can focus on investing in a specific therapeutic segment or divide them into a number of activities or areas for risk minimization. Once the investment period ends, either the generated intellectual property might be claimed or to give to a 3 rd party via out-licensing. As an alternate, the intellectual property might be retained and commercialized by the original companies and its ROI (Return on Investment) is paid to sponsoring companies. Different big pharmaceutical companies like Pfizer, Novartis, etc. have venture capital funds at the corporate level.
1.B) The fully diversified model
In this business model, Pharmaceutical companies expand their horizon from their core capabilities or core business into different related products or services like generics, health management, diagnostics, etc. This facilitates companies in reducing their dependability on Blockbuster medicines.
Excellent Information for starters. Thank you.
Hi there, I found this information very useful for a project I am working on for school. Is there any way you can give me the author’s details and other references so I can reference the above article myself? APA format reference would be much appreciated.
So, you’ve got an idea and you want to start a business —great! Before you do anything else, like seek funding or build out a team, you'll need to know how to write a business plan. This plan will serve as the foundation of your company while also giving investors and future employees a clear idea of your purpose.
Below, Lauren Cobello, Founder and CEO of Leverage with Media PR , gives her best advice on how to make a business plan for your company.
Build your dream business with the help of a high-paying job—browse open jobs on The Muse »
According to Cobello, a business plan is a document that contains the mission of the business and a brief overview of it, as well as the objectives, strategies, and financial plans of the founder. A business plan comes into play very early on in the process of starting a company—more or less before you do anything else.
“You should start a company with a business plan in mind—especially if you plan to get funding for the company,” Cobello says. “You’re going to need it.”
Whether that funding comes from a loan, an investor, or crowdsourcing, a business plan is imperative to secure the capital, says the U.S. Small Business Administration . Anyone who’s considering giving you money is going to want to review your business plan before doing so. That means before you head into any meeting, make sure you have physical copies of your business plan to share.
The four main types of business plans are:
Internal business plans, strategic business plans, one-page business plans.
Let's break down each one:
If you're wondering how to write a business plan for a startup, Cobello has advice for you. Startup business plans are the most common type, she says, and they are a critical tool for new business ventures that want funding. A startup is defined as a company that’s in its first stages of operations, founded by an entrepreneur who has a product or service idea.
Most startups begin with very little money, so they need a strong business plan to convince family, friends, banks, and/or venture capitalists to invest in the new company.
Internal business plans “are for internal use only,” says Cobello. This kind of document is not public-facing, only company-facing, and it contains an outline of the company’s business strategy, financial goals and budgets, and performance data.
Internal business plans aren’t used to secure funding, but rather to set goals and get everyone working there tracking towards them.
As the name implies, strategic business plans are geared more towards strategy and they include an assessment of the current business landscape, notes Jérôme Côté, a Business Advisor at BDC Advisory Services .
Unlike a traditional business plan, Cobello adds, strategic plans include a SWOT analysis (which stands for strengths, weaknesses, opportunities, and threats) and an in-depth action plan for the next six to 12 months. Strategic plans are action-based and take into account the state of the company and the industry in which it exists.
Although a typical business plan falls between 15 to 30 pages, some companies opt for the much shorter One-Page Business Plan. A one-page business plan is a simplified version of the larger business plan, and it focuses on the problem your product or service is solving, the solution (your product), and your business model (how you’ll make money).
A one-page plan is hyper-direct and easy to read, making it an effective tool for businesses of all sizes, at any stage.
Every business plan is different, and the steps you take to complete yours will depend on what type and format you choose. That said, if you need a place to start and appreciate a roadmap, here’s what Cobello recommends:
Before writing your business plan, you’ll want to do a thorough investigation of what’s out there. Who will be the competitors for your product or service? Who is included in the target market? What industry trends are you capitalizing on, or rebuking? You want to figure out where you sit in the market and what your company’s value propositions are. What makes you different—and better?
The purpose of your business plan will determine which kind of plan you choose to create. Are you trying to drum up funding, or get the company employees focused on specific goals? (For the former, you’d want a startup business plan, while an internal plan would satisfy the latter.) Also, consider your audience. An investment firm that sees hundreds of potential business plans a day may prefer to see a one-pager upfront and, if they’re interested, a longer plan later.
Every business plan needs a company description—aka a summary of the company’s purpose, what they do/offer, and what makes it unique. Company descriptions should be clear and concise, avoiding the use of jargon, Cobello says. Ideally, descriptions should be a few paragraphs at most.
A business plan should be centered around the company’s goals, and it should clearly explain how the company will generate revenue. To do this, Cobello recommends using actual numbers and details, as opposed to just projections.
For instance, if the company is already making money, show how much and at what cost (e.g. what was the net profit). If it hasn’t generated revenue yet, outline the plan for how it will—including what the product/service will cost to produce and how much it will cost the consumer.
How will you promote the business? Through what channels will you be promoting it? How are you going to reach and appeal to your target market? The more specific and thorough you can be with your plans here, the better, Cobello says.
What will you do with the money you raise? What are the first steps you plan to take? As a founder, you want to instill confidence in your investors and show them that the instant you receive their money, you’ll be taking smart actions that grow the company.
Creating a business plan is in some ways akin to building a legal case, but for your business. “You want to tell a story, and to be as thorough as possible, while keeping your plan succinct, clear, interesting, and visually appealing,” Cobello says. “Supporting documents could include financial projects, a competitive analysis of the market you’re entering into, and even any licenses, patents, or permits you’ve secured.”
A business plan is an individualized document—it’s ultimately up to you what information to include and what story you tell. But above all, Cobello says, your business plan should have a clear focus and goal in mind, because everything else will build off this cornerstone.
“Many people don’t realize how important business plans are for the health of their company,” she says. “Set aside time to make this a priority for your business, and make sure to keep it updated as you grow.”
By Nyah Phengsitthy
Boehringer Ingelheim’s attempt to block the Medicare Drug Price Negotiation Program was rejected by a federal judge Wednesday, handing another win to the Biden administration in the war of lawsuits challenging his signature health plan.
Chief Judge Michael P. Shea of the US District Court for the District of Connecticut denied all of Boehringer Ingelheim Pharmaceuitcals Inc.'s claims that the Biden administration’s program is unconstitutional.
At issue is whether the signature Inflation Reduction Act plan to lower the costs of the prescription drugs Medicare spends the most on is unconstitutional by forcing the company to agree to a maximum fair price for its drug. Its diabetes drug Jardiance was selected as one of the 10 medicines in the first negotiation round .
The manufacturer argued the program violates the First Amendment prohibition on compelled speech, Fifth Amendment due process and takings clauses, Eighth Amendment excessive fines clause, the Administrative Procedure Act, and the unconstitutional conditions doctrine.
“I find that BI’s participation in Medicare and Medicaid is voluntary, even if BI has a considerable economic incentive to participate,” Shea wrote.
“With all the resources at the federal government’s disposal, private corporations will often have an incentive to participate in federal programs. The Fifth Amendment does not prevent the federal government from placing conditions on participation in those programs,” he added.
The Obama appointee went on in the 47-page opinion to say the drugmaker hasn’t been deprived of its “property interest in its confidential data regarding Jardiance,” because BI was not required to turn over any data until Oct. 2, 2023.
Boehringer “had an option to withdraw from Medicare and Medicaid before that point,” he wrote.
As for the drugmaker’s First Amendment claim, a prime argument of other drugmaker and industry lawsuits challenging the program, Shea wrote the “argument finds no support in precedent.”
“Indeed, the IRA requires BI to communicate in various ways, including, arguably, by signing the Manufacturer Agreement and by making a written counteroffer that must ‘be justified based on [the statutory factors],’” Shea wrote. “But as with ‘typical price regulations,’ the words CMS requires manufacturers to use are just an incidental means to CMS’ goal of regulating drug prices.”
Shea also ruled that even if Boehringer could show irreparable harm, it cannot show certainty of success on the merit, in response to the manufacturer’s Eighth Amendment argument.
“BI cannot meet this demanding standard because its Eighth Amendment claim is novel and, so, far from certain,” Shea wrote. “BI has identified no case in which a court has applied the Excessive Fines Clause to a monetary amount that was not connected to criminal conduct or a criminal proceeding.”
The case is Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services , D. Conn., No. 3:23-cv-01103, opinion 7/3/24.
To contact the reporter on this story: Nyah Phengsitthy in Washington at [email protected]
To contact the editor responsible for this story: Karl Hardy at [email protected]
Learn about bloomberg law.
AI-powered legal analytics, workflow tools and premium legal & business news.
Log in to keep reading or access research tools.
Advertisement
Supported by
The justices rejected a bankruptcy settlement maneuver that would have protected members of the Sackler family from civil claims related to the opioid epidemic.
By Abbie VanSickle
Reporting from Washington
The Supreme Court said on Thursday that members of the Sackler family cannot be shielded from liability for civil claims related to the opioid epidemic, jeopardizing a bankruptcy plan that would have offered such protection in exchange for channeling billions of dollars toward addressing the crisis.
In a 5-to-4 decision, the justices found that the deal, carefully negotiated over years with states, tribes, local governments and individuals, had broken a basic tenet of bankruptcy law by shielding members of the Sackler family from lawsuits without the consent of those who might sue.
The plan for Purdue Pharma, the maker of the prescription painkiller OxyContin, the drug widely considered to have ignited the crisis, was unusual because it offered broad protections that the Sackler family, who controlled the company, had demanded for years even as the Sacklers avoided declaring bankruptcy themselves.
“The Sacklers have not filed for bankruptcy and have not placed virtually all their assets on the table for distribution to creditors, yet they seek what essentially amounts to a discharge,” Justice Neil M. Gorsuch wrote, joined by Justices Clarence Thomas, Samuel A. Alito Jr., Amy Coney Barrett and Ketanji Brown Jackson.
While he acknowledged that the decision left the plan in limbo, Justice Gorsuch wrote that the threat of future lawsuits from opioid victims, states, government entities and others might compel the Sacklers “to negotiate consensual releases on terms more favorable to opioid victims.”
“If past is prologue,” Justice Gorsuch wrote, citing the U.S. Trustee Office, which challenged the deal, “there may be a better deal on the horizon.”
We are having trouble retrieving the article content.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in .
Want all of The Times? Subscribe .
COMMENTS
Traditionally, a marketing plan includes the four P's: Product, Price, Place, and Promotion. For a pharmaceutical company, your marketing strategy should include the following: Product: In the product section, you should reiterate the type of pharmaceutical business that you documented in your company overview.
ClickUp's Business Plan Template for Pharmaceutical Companies provides a comprehensive solution for creating and managing your pharmaceutical business plan. Here are the main elements of this template: Custom Statuses: Keep track of the progress of each section of your business plan with statuses like Complete, In Progress, Needs Revision, and ...
A Sample Pharmaceutical Company Business Plan Template 1. Industry Overview. The Generic pharmaceutical and medicine manufacturing companies primarily develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals.
Biopharma M&A deal value more than doubled between 2017 and 2019, from $138 billion to $336 billion, and valuations reached all-time highs. Most of those deals involved midsized biotech companies, for which the average premium paid was close to 70%, with an average EV/sales multiple of nearly 8x. All in all, close to 60% of new therapeutic ...
Debbie. March 19, 2024. Business Plan. Creating a comprehensive business plan is crucial for launching and running a successful pharmacy. This plan serves as your roadmap, detailing your vision, operational strategies, and financial plan. It helps establish your pharmacy's identity, navigate the competitive market, and secure funding for growth.
Cash at End of Period. $87,016. $45,597. $74,292. Download This Plan. Explore a real-world pharmacy business plan example and download a free template with this information to start writing your own business plan.
Research. Doing the necessary research is a vital step to starting your own pharmaceutical company. It is important to dive deep into the industry, research potential competitors, and understand the regulations that may affect the business. Research will help establish a strong foundation for a successful business model.
Before you start writing a business plan, spend as much time as you can reading through some samples of medical and health-related business plans.. Industry Overview. The pharmaceutical industry stood at a market value of 1.27 trillion dollars in 2020 and has shown remarkable growth in the past two decades.. The advancement of research and development in the medical field has played a ...
Pharmacy Business Plan. If you want to start an independent pharmacy or expand your current one, you need a business plan. Over the past 20+ years, we have helped over 5,000 entrepreneurs and business owners create business plans to start and grow their pharmacy businesses.
A business plan has 2 main parts: a financial forecast outlining the funding requirements of your pharmaceutical manufacturer and the expected growth, profits and cash flows for the next 3 to 5 years; and a written part which gives the reader the information needed to decide if they believe the forecast is achievable.
How to Start a Pharma Company. David Blok | Posted on September 19, 2023 | Updated on March 26, 2024. Introduction. Step 1: Market Research and Pharmaceutical Business Ideas. Step 2: Creating a Business Plan. Step 3: Regulatory Compliance and Legalities. Step 4: Team Building and Talent Acquisition. Step 5: Location and Infrastructure.
A pharmaceutical company is a business entity that specializes in the research, development, manufacturing, and distribution of medications and pharmaceutical ... Step 1: Business Plan Development. The detailed business plan should outline the specific pharmaceutical products to be manufactured or sold, describe the target audience, explain the ...
The pharmaceutical industry is under immense pressure by external and internal stakeholders. Government and National Health Services are monopsonic practices. Pharmaceutical companies are criticised for high prices, over-intensive sales and marketing activities, presents to medical doctors, clinical trials and industry - government alliances.
Business planning. After conducting market research, the next step in starting a pharmaceutical wholesale business is to create a comprehensive business plan. This plan should outline your business goals, strategies, and expected outcomes. Key elements of a business plan for a pharmaceutical wholesale business might include:
As an entrepreneur you can also start a small pharmacy or drug store in your locality. Sample pharmacy business plans and template will guide you. We, at OGSCapital, help you with this. Our executives have all the expertise for helping you to develop an appropriate strategy to fulfill your all objectives.
Research and development: Since it takes an average of 10 years for a drug to reach the market, and typically six to seven of those years are in clinical trials, plan for approximately three years ...
Starting a Pharmaceutical Company: Tips for A Successful Venture. Develop a strong business plan that includes understanding the regulatory landscape and conducting a market analysis. Construct the production area with help from cleanroom design and construction services. Build a solid regulatory strategy to comply with FDA and other agencies.
The company described in this plan has moved beyond the initial start-up phase and is now seeking investors to finance its growth. Much of the plan, therefore, is geared toward persuading, explaining, and reassuring potential investors that the company (which produces a therapeutic, topical pain cream), is well-managed and stable.
Pharma 2.0 is a service company consisting of a web portal and additional services that offer. a peer-to-peer networking environment for corporations, universities, and research facilities. to locate, coordinate and collaborate on various projects without the necessity of extensive. resources.
ClickUp's Pharmaceutical Company Strategic Plan Template is designed to help executive leadership teams outline their long-term goals and objectives with ease. This comprehensive template allows you to: Define research and development priorities to drive innovation and stay at the forefront of medical advancements.
Sample Business Plan For Pharmaceutical Sales Nat Chiaffarano MBA ... and out-of-the-box ideas to launch a successful Medical Spa Company. This Business Plan book provides the updated, relevant content needed to become much more knowledgeable about starting a profitable medical spa. The fill-in-the-blank
Lastly, address any funding needs in the "ask" section of your executive summary. 2. The presentation of the company. The second section in your pharmaceutical wholesaler's business plan should focus on the structure and ownership, location, and management team of the company.
2. Customer Segments. The target customers of pharmaceutical companies under the blockbuster business model are mainly doctors and patients as the companies cover a mass market. Moreover, various health institutions like hospitals, clinics, pharmacies, etc. also come under customer segment portfolio. 3.
pharmaceutical products including African Traditional Medicines that are relevant to local health problems. The pharmaceutical programme is one of the priorities under the RISDP. 1.3.3 It is against this background that a Business Plan has been developed in order to operationalize the Programme. The Plan has six main sections which include:
Every business plan needs a company description—aka a summary of the company's purpose, what they do/offer, and what makes it unique. Company descriptions should be clear and concise, avoiding the use of jargon, Cobello says. Ideally, descriptions should be a few paragraphs at most. 4. Explain and show how the company will make money
Gilead Sciences overview. Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus ...
At issue is whether the signature Inflation Reduction Act plan to lower the costs of the prescription drugs Medicare spends the most on is unconstitutional by forcing the company to agree to a maximum fair price for its drug. Its diabetes drug Jardiance was selected as one of the 10 medicines in the first negotiation round.
Walgreens is set to close a substantial number of its roughly 8,600 locations across the United States as the company looks to reset the struggling pharmaceutical chain's business.
MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Bracco and Blue Earth Diagnostics Ltd, a Bracco company and recognized leader in the development and commercialization of innovative PET ...
The plan for Purdue Pharma, the maker of the prescription painkiller OxyContin, the drug widely considered to have ignited the crisis, was unusual because it offered broad protections that the ...